YouTube2Text

Vasculites: Aula de Curso Intensivo Residência Médica com Profa. Taysa Moreira — Transcript

by Estratégia MED · 14,456 words · 2,389 segments · language en · Watch on YouTube

Full transcript

  1. 0:41When I started the audio lessons, I
  2. 0:42felt very secure, and the results I
  3. 0:44have today are no accident. So, without
  4. 0:46a doubt, our hard work pays off, but
  5. 0:48the materials and the teachers truly
  6. 0:50held my hand and helped me get there.
  7. 0:52Studying for hours on end just didn't
  8. 0:54work for me. So, very long classes are
  9. 0:56difficult to get through. Having
  10. 0:58materials, whether in class, text, or
  11. 1:00flashcard format, that are a bit more
  12. 1:03fragmented allows us to study more at
  13. 1:05our own pace, right? The study schedule
  14. 1:08also helped guide me, and as you
  15. 1:10mentioned, the multiple platforms
  16. 1:11really help too. Whenever I had some
  17. 1:14time, I’d read a summary, do some
  18. 1:15practice questions, go through a
  19. 1:17question list, watch a short class, a
  20. 1:19summary lecture, or even listen to the
  21. 1:21strategy cast, which helps us make the
  22. 1:23most of the time we have, especially
  23. 1:25since life has become so busy lately.
  24. 1:27Right?
  25. 1:28So I tested it out and said: "This is
  26. 1:29the course I’m going to take." It’s
  27. 1:31a fair course, the classes are very
  28. 1:33good and straight to the point. It
  29. 1:36teaches exactly what I need to know.
  30. 1:39And honestly, most of my doubts, even
  31. 1:41though I sent a million questions, were
  32. 1:43resolved by the classes and the books.
  33. 1:45So I totally agree and would do it
  34. 1:48again. I think Estratégia gives great
  35. 1:52direction regarding what is important
  36. 1:55to study so you don’t waste time on
  37. 1:57things you can go through faster,
  38. 2:00keeping you focused on what you set out
  39. 2:03to do. What I liked most was that: the
  40. 2:07methodology really helped me a lot,
  41. 2:09especially the spaced repetition and
  42. 2:12the question-solving method, which
  43. 2:14provided guidance right within the
  44. 2:17questions themselves. I felt like
  45. 2:20everything was very well-integrated and
  46. 2:22very well-organized within that study
  47. 2:24plan. For me, that was a huge help.
  48. 3:16When I started using it, I felt very
  49. 3:18secure, and the results I have today
  50. 3:20are no accident. So, without a doubt,
  51. 3:22our hard work pays off, but the
  52. 3:24materials and the teachers truly held
  53. 3:26my hand and helped me get there.
  54. 3:28Studying for hours on end just didn't
  55. 3:30work for me. So, very long classes are
  56. 3:31difficult to get through. Having
  57. 3:33materials, whether in class, text, or
  58. 3:36flashcard format, that are a bit more
  59. 3:38fragmented allows us to study more at
  60. 3:40our own pace, right? This schedule also
  61. 3:44helped to guide me, and as you
  62. 3:45mentioned, the multiple platforms are
  63. 3:47really helpful. Whenever I had time,
  64. 3:49I'd read a summary, do some questions,
  65. 3:52a question list, watch a short class, a
  66. 3:54summary lecture, or even listen to the
  67. 3:56Estrategia Cast, which helps us make
  68. 3:57the most of the time we have,
  69. 3:59especially since things have gotten so
  70. 4:01busy lately.
  71. 4:02Right?
  72. 4:03So I tested it out and said, "This is
  73. 4:05the course I’m going to take." It's a
  74. 4:07fair course, the classes are very good,
  75. 4:10straight to the point, and they teach
  76. 4:12exactly what I need to know. And
  77. 4:14honestly, most of my questions, even
  78. 4:16though I sent a million of them, were
  79. 4:18resolved by the classes and the books.
  80. 4:21So I totally agree, and I would do it
  81. 4:24again. I think Estrategia provides
  82. 4:27great guidance regarding what’s
  83. 4:29important to study so you don’t waste
  84. 4:32time on things you can go through
  85. 4:35faster, and you remain objective in
  86. 4:37what you set out to do. What I liked...
  87. 4:41what I liked most was this: the
  88. 4:43methodology helped me a lot, especially
  89. 4:46the spaced repetition and the
  90. 4:48question-solving method that included
  91. 4:51guidance within the questions
  92. 4:53themselves. I felt like everything was
  93. 4:56very well integrated and organized
  94. 4:58within that study plan. For me, that
  95. 5:00helped a lot. When I started using the
  96. 5:53material, I felt very secure, and the
  97. 5:54results I have today are no coincidence
  98. 5:56. So, without a doubt, of course our
  99. 5:58effort is worth it, but the material is
  100. 6:00too.
  101. 6:22Hi everyone, good evening. How are you
  102. 6:24all doing? I’m Professor Taísa
  103. 6:26Moreira, and from now on we’ll be
  104. 6:28having another live session, a
  105. 6:30rheumatology class in live format.
  106. 6:32It’s 7:01, so we’ve started on time
  107. 6:35, and I’d like to say good evening to
  108. 6:37you all. I want you all to participate
  109. 6:39right now. For those already online and
  110. 6:41those joining the class, please say
  111. 6:43good evening and tell us where you're
  112. 6:45from. Whether you’re studying here
  113. 6:47for direct access, studying for the
  114. 6:49Revalida, or just watching the classes
  115. 6:51here on YouTube. Today is a special
  116. 6:53class for our intensive course, a
  117. 6:55course that is for sale, if I'm not
  118. 6:56mistaken, still with a great discount,
  119. 6:58so it's well worth checking out. Our
  120. 7:00educational team is here in the chat,
  121. 7:02so if you have any questions, feel free
  122. 7:04to talk to them. And before we begin,
  123. 7:06those usual quick reminders, right? So
  124. 7:09subscribe to the channel now, check if
  125. 7:11you're subscribed; we think we are, but
  126. 7:14we aren't. So click there, turn on the
  127. 7:16bell to get notifications for the, I
  128. 7:19don't know, dozens of classes we have
  129. 7:21throughout the week, every day. There's
  130. 7:24a lot of content from every possible
  131. 7:26area: Acesso Direto, Revalida, R + Mais
  132. 7:28. It’s constant. And besides
  133. 7:31commenting here in the chat, take the
  134. 7:33link to this live stream and send it to
  135. 7:35someone studying with you, out there in
  136. 7:37the battles of studying, right?
  137. 7:39Remembering that it's getting closer,
  138. 7:41guys. October and November are coming,
  139. 7:43exam season. So anything we can do to
  140. 7:45speed up your studies, we will. And the
  141. 7:48intensive course is a great option,
  142. 7:50okay? Let me take a look at the chat
  143. 7:52here. You know that when we do this
  144. 7:54live class here—Augusto, good evening
  145. 7:56. Keep joining. When we do these live
  146. 7:59classes, we interact with you at the
  147. 8:01beginning and the end, because
  148. 8:02afterwards this class is edited and
  149. 8:04goes onto the Estratégia platform. For
  150. 8:07those who are "corujinhas," for those
  151. 8:08who are Estratégia Med students, you
  152. 8:10have full access to this class, okay?
  153. 8:11So, in this beginning part I can
  154. 8:13interact with you, but once I get into
  155. 8:16the lesson, I won't be able to anymore,
  156. 8:18okay? So, what do we do? I’ll start
  157. 8:21by chatting with you here. Any
  158. 8:24questions that come up during the class
  159. 8:26, really any at all, leave them in the
  160. 8:27chat because at the end I'll come back
  161. 8:29and answer them, okay? Also, I
  162. 8:31remembered that today is the last day
  163. 8:33for the intensive course discount, okay
  164. 8:35? And if I'm not mistaken, the
  165. 8:37intensive plus the question bank is an
  166. 8:38unmissable deal. Like I said, it’s
  167. 8:41coming up, the exams are near, but it
  168. 8:43is totally possible to prepare with the
  169. 8:45intensive schedule for the exams coming
  170. 8:47in October and November, okay? So take
  171. 8:50advantage, it’s the last day; the
  172. 8:52team will probably leave the link for
  173. 8:53you down below, alright? So folks, I
  174. 8:56think we've given people enough time to
  175. 8:58join, no problem at all if you join
  176. 9:00later. Thaís, good evening. Jane
  177. 9:02Salvador, good evening, everyone. Do
  178. 9:04keep joining, keep commenting, and as
  179. 9:06we go through the class, keep leaving
  180. 9:08your comments there too, and I’ll
  181. 9:10check them at the end. This is an
  182. 9:13extensive class in its own way. We are
  183. 9:15going to talk about many diseases. So,
  184. 9:18I'll say right away, since this is an
  185. 9:20intensive course, we won't go into
  186. 9:21detail on all of them. I will cover the
  187. 9:24main points, the things that need to
  188. 9:27stick in your head to form an image of
  189. 9:29each of these vasculitides, okay? So,
  190. 9:33we will talk about several diseases
  191. 9:34here that, while quite similar in some
  192. 9:36aspects, have their own peculiarities.
  193. 9:39And what I want you to pay attention to
  194. 9:41is exactly that, the general context
  195. 9:43that unites these diseases, which I
  196. 9:44will talk about at the very beginning
  197. 9:46of the class. And after that, pay close
  198. 9:49attention to the peculiarities of each
  199. 9:50one. This is the key to solving exam
  200. 9:53questions about these diseases, okay?
  201. 9:56Some appear more often on exams, others
  202. 9:59less so. Throughout the class, I will
  203. 10:01reinforce this, but that’s it. An
  204. 10:03intensive course is a fast pace, it’s
  205. 10:04something more direct, the highlights
  206. 10:06of these conditions, alright? So, I
  207. 10:08imagine about an hour of class in total
  208. 10:11, and when I finish, I’ll return to
  209. 10:14check the chat with you, okay? So, look
  210. 10:16, I’ll play the intro, and as soon as
  211. 10:18I return, I’ll start our class
  212. 10:20without breaks, and I’ll come back at
  213. 10:22the end, okay? So, just wait a few
  214. 10:23seconds and I'll be right back. Hello,
  215. 10:43everyone. Welcome to another class of
  216. 10:45our Intensive course. Today our class
  217. 10:48is about vasculitis. I am Professor
  218. 10:51Taísa Moreira, professor of
  219. 10:53rheumatology clinical practice here at
  220. 10:54Estratégia. And for us to discuss the
  221. 10:57topic of vasculitis, there is a
  222. 10:59systematization that really helps in
  223. 11:01learning this content, which is
  224. 11:03extensive. We are talking here about
  225. 11:05several diseases, complex diseases that
  226. 11:08sometimes have a difficult diagnosis.
  227. 11:10The questions involving these diseases
  228. 11:12are generally questions that have a
  229. 11:14higher level of complexity than what we
  230. 11:16see, for example, compared to other
  231. 11:18rheumatological diseases. So, full
  232. 11:21attention here, okay? And how are we
  233. 11:23going to organize this class? Following
  234. 11:25this schedule which is based on the
  235. 11:27caliber of the vessels predominantly
  236. 11:30affected in each of these vasculitides,
  237. 11:32okay? So, we will start with a general
  238. 11:34overview and then we will go through
  239. 11:35them in order. Large-vessel vasculitis,
  240. 11:38medium-vessel. Small-vessel and finally
  241. 11:41those that affect vessels of all
  242. 11:43calibers, variable-vessel vasculitis.
  243. 11:45Okay? So, to not waste any more time,
  244. 11:48let's start with the definition. What
  245. 11:51unites all these diseases that we will
  246. 11:53discuss today? Basically, here we have
  247. 11:57a group, right, which as the name
  248. 11:59implies, of diseases that share an
  249. 12:01inflammatory process in the blood
  250. 12:03vessels. However, this is a quite
  251. 12:07heterogeneous group. We have here
  252. 12:10diseases that have a localized, benign
  253. 12:12character, that do not have systemic
  254. 12:14involvement, do not have involvement of
  255. 12:16vital organs, for example, vasculitis
  256. 12:18limited to the skin. But when we are
  257. 12:21talking about systemic vasculitis,
  258. 12:24which is our focus here today, things
  259. 12:26change. We also have those that have a
  260. 12:29milder behavior, but we have the
  261. 12:31possibility of vital organ involvement.
  262. 12:34Central nervous system, heart, kidneys.
  263. 12:37And these vasculitis, once they affect
  264. 12:39these organs, can lead to high
  265. 12:41morbidity and mortality rates, okay? So
  266. 12:44there will be a little bit of
  267. 12:45everything here. It is important that
  268. 12:46you understand what unites them and
  269. 12:48then what differentiates them; that is
  270. 12:50what we are going to emphasize here,
  271. 12:52okay? Regarding what this inflammation
  272. 12:55in the vessel wall causes, imagine the
  273. 12:58following: you have a normal vessel
  274. 12:59here, magnified, with its lumen
  275. 13:01preserved, the wall, right, with its
  276. 13:03thickness preserved. As we begin to
  277. 13:07show inflammation, an infiltration of
  278. 13:10inflammatory cells, an activation of
  279. 13:12enzymes with proteolytic action,
  280. 13:14metalloproteinases, we see a
  281. 13:16destruction of this wall structure and
  282. 13:19a thickening of this wall. With the
  283. 13:23thickening of the wall, what happens?
  284. 13:26The reduction of this lumen, which is
  285. 13:28where the blood passes through. It is
  286. 13:31where the blood will pass, which will
  287. 13:32go to organs, tissues, structures. And
  288. 13:34if I reduce the lumen, I automatically
  289. 13:37reduce the blood flow to that structure
  290. 13:39. Reducing the blood flow or in some
  291. 13:41cases, even making it absent, what do
  292. 13:43we cause? We cause ischemia of that
  293. 13:46structure. So, basically, when we talk
  294. 13:49here about vascular manifestations of
  295. 13:51these diseases, remember this: this
  296. 13:53alteration in the vessel wall structure
  297. 13:56, lumen reduction, vessel stenosis,
  298. 13:58because this will justify the clinical
  299. 14:00pictures that we will discuss from now
  300. 14:03on. Regarding classification, we can
  301. 14:06classify in different ways, but the
  302. 14:08most important one, and the one you
  303. 14:10have to know by heart, really memorized
  304. 14:12, is the classification regarding the
  305. 14:14caliber of the vessels predominantly
  306. 14:16affected. Especially for medium and
  307. 14:19small vessel ones, there may be an
  308. 14:21intersection and thus vessels of
  309. 14:23multiple calibers may be affected, okay
  310. 14:25? But we must remember, each of them
  311. 14:27has a predominant vessel caliber. It is
  312. 14:30from there that this large vessel
  313. 14:32classification arises. medium vessels
  314. 14:34and small vessels, okay? It is
  315. 14:36fundamental that you memorize this. And
  316. 14:38in this little diagram, we basically
  317. 14:40divide these vasculitis that we will
  318. 14:42see from now on into these groups. So,
  319. 14:44for large vessel vasculitis, there are
  320. 14:46two you have to remember: Takayasu
  321. 14:48arteritis and giant cell arteritis or
  322. 14:51temporal arteritis. In adults, for
  323. 14:53medium vessel vasculitis, polyarteritis
  324. 14:55nodosa. Kawasaki disease is a
  325. 14:58predominantly medium-sized vessel
  326. 15:00vasculitis, but it is discussed in
  327. 15:02pediatrics, okay? That's why it's not
  328. 15:04here. As for small vessels, we have
  329. 15:06most of the vasculitis we will discuss
  330. 15:09today, those associated with ANCA. And
  331. 15:12here we have Wegener’s,
  332. 15:13granulomatosis with polyangiitis,
  333. 15:15Churg-Strauss, eosinophilic
  334. 15:17granulomatosis with polyangiitis, and
  335. 15:19microscopic polyangiitis. And we also
  336. 15:22have small vessel vasculitis mediated
  337. 15:24by immune complexes. We will discuss
  338. 15:27cryoglobulinemia here, because
  339. 15:29Henoch-Schönlein purpura or IgA
  340. 15:31vasculitis, just like Kawasaki disease,
  341. 15:33will be discussed in pediatrics. There
  342. 15:36is a specific lecture for it, okay? So,
  343. 15:38just to show you that you need to
  344. 15:39memorize this. Look at this exam
  345. 15:41question, this one, from the Presidente
  346. 15:43Prudente Regional Hospital. Regarding
  347. 15:45primary vasculitis, what can be
  348. 15:47correctly stated as an example of large
  349. 15:49vessel involvement? If it's large
  350. 15:52vessels, who should we be looking for?
  351. 15:54Either Takayasu or giant cell arteritis
  352. 15:57. And where do we find it here in the
  353. 15:59alternative for Takayasu arteritis. All
  354. 16:02the others are not classified within
  355. 16:05this group, okay? Remembering that the
  356. 16:07goal of the questions here is just to
  357. 16:09exemplify a concept we discussed and
  358. 16:11hammer it into your head. The complete
  359. 16:14and clear solution to these questions
  360. 16:15is in the bank, alright? So let's start
  361. 16:18with exactly these large vessel
  362. 16:20vasculitis and let's start with the one
  363. 16:22that was the answer to the question,
  364. 16:24which is Takayasu arteritis. So here we
  365. 16:27are talking about a disease that is
  366. 16:29known by other names, which actually
  367. 16:31reflects a lot of what the disease
  368. 16:33causes. So, Takayasu is also known as
  369. 16:36pulseless disease, remember pulseless.
  370. 16:39This is a phenomenal tip for the
  371. 16:41physical examination of these patients
  372. 16:43and is also called aortic arch syndrome
  373. 16:45, because basically the vessels
  374. 16:47predominantly affected in this
  375. 16:48vasculitis are those that branch off
  376. 16:50the aortic arch going up and down. Got
  377. 16:53it? Returning here in terms of
  378. 16:55definition, we have the involvement of
  379. 16:57those large vessels that descend from
  380. 16:59the aorta, its main branches. So here
  381. 17:02we remember, for example, the
  382. 17:04subclavian and its tributaries, the
  383. 17:06carotid, vertebral, and renal arteries.
  384. 17:09These are the main ones, but of course,
  385. 17:11occasionally one or another might be
  386. 17:12affected, such as the pulmonary
  387. 17:14arteries. It's just not the classic
  388. 17:15presentation of the disease, okay?
  389. 17:17Thinking about epidemiology, remember:
  390. 17:20"Takayasu is a vasculitis of young
  391. 17:22adults, 20 to 30 years old at most."
  392. 17:25And the female sex is more affected.
  393. 17:27This is extremely important because the
  394. 17:28next large-vessel vasculitis I will
  395. 17:30discuss is the vasculitis of the
  396. 17:31elderly. "So, Takayasu is for the young
  397. 17:33, giant cell arteritis is for the
  398. 17:34elderly. Regarding the clinical picture
  399. 17:37. All systemic vasculitis we will
  400. 17:40discuss from now on are diseases that
  401. 17:43cause systemic inflammation, so
  402. 17:45findings like low-grade fever, fatigue,
  403. 17:48asthenia, weight loss, myalgia, and
  404. 17:50arthralgia can be part of the clinical
  405. 17:52picture of these diseases, okay? So, a
  406. 17:56constitutional presentation can appear
  407. 17:58in any of them, but that's not what
  408. 18:00will solve the puzzle of which
  409. 18:02vasculitis it is in a given question.
  410. 18:04It is the typical manifestations of
  411. 18:06each one. And in the case of Takayasu,
  412. 18:08we have to remember the vascular
  413. 18:10symptoms that result from what? Exactly
  414. 18:13from that stenosis I showed you in the
  415. 18:15diagram, that reduction in the vessel
  416. 18:17caliber. Due to this stenosis, what
  417. 18:19will we present? Upper limb
  418. 18:21claudication. So, pain, paresthesia,
  419. 18:25discomfort when lifting the upper limbs
  420. 18:27here. This generally results from
  421. 18:30subclavian stenosis. Following with
  422. 18:32neurological symptoms, when it affects
  423. 18:34the carotid or vertebral arteries, it
  424. 18:36causes headache, vertigo, tinnitus, and
  425. 18:38even stroke in young patients. We must
  426. 18:41remember that when it affects the
  427. 18:43thoracic aorta, it can be a cause of
  428. 18:44angina. Angina, both thoracic and
  429. 18:47abdominal, when it affects intestinal
  430. 18:50or renal arteries, in short. And it is
  431. 18:54also a cause of hypertension, including
  432. 18:56renovascular hypertension, a cause of
  433. 18:58secondary hypertension. You can
  434. 19:01remember that from cardiology. Now,
  435. 19:03this is the general clinical picture.
  436. 19:06In general, the cherry on top for you
  437. 19:08to clinch the Takayasu diagnosis comes
  438. 19:10from this slide. So, focus here on the
  439. 19:13blood pressure difference between the
  440. 19:15upper limbs, as there is generally a
  441. 19:17tendency for more stenosis on the left.
  442. 19:20So you might have, for example, a very
  443. 19:23low BP, 70/50 here in the left upper
  444. 19:25limb and a normal or even elevated one
  445. 19:27if I have renovascular hypertension on
  446. 19:29the right. So this is the first finding
  447. 19:32. Second, the absence or reduction of
  448. 19:35pulses. Fundamental to remember. This
  449. 19:38even gives the disease its name. So, if
  450. 19:41you see a patient who presents with any
  451. 19:43clinical signs we mentioned and on
  452. 19:44physical exam has a reduction or
  453. 19:46absence of peripheral pulses, think of
  454. 19:48Takayasu, especially if it's a young
  455. 19:49patient, okay? And to wrap up, due to
  456. 19:52the stenosis, bruits over the great
  457. 19:55vessels. And keeping these findings in
  458. 19:58mind, I’ll jump right to imaging, to
  459. 20:00the imaging findings, be it an
  460. 20:02arteriography, which is considered the
  461. 20:04gold standard but is rarely performed
  462. 20:06today due to technical difficulties
  463. 20:08with access and potential adverse
  464. 20:10events. That is why in arteriography,
  465. 20:13MRA, or CTA, what do we see? These
  466. 20:16spots right here, of stenosis, where
  467. 20:18there is no blood flow. And added to
  468. 20:21that, in these vasculitides, what will
  469. 20:23we notice over time? The weakening of
  470. 20:25that wall which is thickened, the wall
  471. 20:28keeps weakening, tending toward the
  472. 20:30formation of dilations, aneurysmal
  473. 20:32dilations. So, often in the imaging of
  474. 20:35these patients, we find areas of
  475. 20:37stenosis alternating with areas of
  476. 20:39aneurysmal dilation, okay? It is
  477. 20:41another component of these diseases.
  478. 20:43There are no specific tests here.
  479. 20:45Basically, the findings are all due to
  480. 20:47systemic inflammation: high CRP, ESR,
  481. 20:49sometimes thrombocytosis, anemia of
  482. 20:51chronic disease. And regarding
  483. 20:55treatment, memorize this from now on.
  484. 20:59For basically all the vasculitides we
  485. 21:01are going to discuss, except for the
  486. 21:03last one, there is a drug that is the
  487. 21:05drug of choice for the initial
  488. 21:06treatment of these diseases, whether
  489. 21:08oral, intravenous, or topical, but
  490. 21:10it’s the glucocorticoid, the key drug
  491. 21:12for the initial treatment of these
  492. 21:14systemic vasculitides, okay? So the
  493. 21:17dose and the route of administration
  494. 21:18will depend on the severity, but don't
  495. 21:20worry because this rarely appears in
  496. 21:22terms of direct access, and when it
  497. 21:24does, I’ll show you here in a
  498. 21:25question, okay? So just remember it’s
  499. 21:27glucocorticoid; for refractory disease,
  500. 21:29what do we do in Rheumatology? We add
  501. 21:32an immunosuppressant, which can be a
  502. 21:33synthetic immunosuppressant or a
  503. 21:35biological immunosuppressant. Okay? A
  504. 21:38little question for us to solidify this
  505. 21:39. First one, whoops, UNESP, a really
  506. 21:42cool question, okay? Let me go back
  507. 21:44here since I already spoiled the answer
  508. 21:47key. A 34-year-old young woman, pain
  509. 21:51and tingling in the left upper limb for
  510. 21:53about 2 years, mainly during intense
  511. 21:55exertion. This here, folks, is the
  512. 21:58so-called claudication that I showed
  513. 22:00you. In terms of medical history, this
  514. 22:03patient has nothing relevant. And look
  515. 22:05at her physical exam: radial and ulnar
  516. 22:08pulses palpable in the right upper limb
  517. 22:10, but in the left, where she has the
  518. 22:12pain and tingling, look, pulses are not
  519. 22:14palpable. She has forearm pain
  520. 22:17reproduced by lifting the limbs and
  521. 22:19performing repetitive gripping
  522. 22:21maneuvers. So when we lift the limb,
  523. 22:24when we keep performing gripping
  524. 22:26maneuvers, what are we testing? Our
  525. 22:28vasculature, but in this case it won't
  526. 22:30respond because there is stenosis,
  527. 22:32there is low flow, okay? Continuing
  528. 22:34here, slowed perfusion in the left
  529. 22:37upper limb compared to the right. And
  530. 22:40we notice that in the lower limbs there
  531. 22:42is no change. And then it asks for the
  532. 22:44main diagnostic hypothesis. It's just
  533. 22:47the picture I told you about, a young
  534. 22:49woman with upper limb claudication, in
  535. 22:50this case the left one, who presents
  536. 22:52with reduced pulses in that upper limb.
  537. 22:55We have to think of Takayasu's
  538. 22:56arteritis. And in this question, two
  539. 22:59are left, C and D. And it asks for the
  540. 23:01treatment. Initial treatment for
  541. 23:03Takayasu's is medication, it's
  542. 23:05corticosteroid and it's a chronic
  543. 23:07disease that must be monitored.
  544. 23:09Deobstruction with wire, art, remember
  545. 23:11that from surgery. This is for when I
  546. 23:13have, for example, an embolus,
  547. 23:14something that is actually amenable to
  548. 23:16deobstruction. This is not the case
  549. 23:17here. It is inflammation in the vessel
  550. 23:19wall, it is glucocorticoid. Alright.
  551. 23:21Answer D. And the next one, let me put
  552. 23:24it here. Takayasu's shows up a lot on
  553. 23:26the exam, you know folks? That's why I
  554. 23:27included two little questions. This one
  555. 23:29is from UFRJ. We have a 25-year-old
  556. 23:33woman previously healthy who has an
  557. 23:35ischemic stroke. Young woman with
  558. 23:38ischemic stroke. We already start
  559. 23:40thinking about some differentials.
  560. 23:42Among these differentials, what is the
  561. 23:44disease that presents with absence of
  562. 23:47pulse, in this case, in the left radial
  563. 23:49artery and the right brachial one? In
  564. 23:52other words, a young woman with a
  565. 23:54stroke, some type of uh ischemic stroke
  566. 23:56, right? So, some type of involvement
  567. 23:59of vessels, right, that go to the uh
  568. 24:01intracranial space, were affected and
  569. 24:03added to this, we have pulse reduction
  570. 24:05in both upper limbs. There's no way, it
  571. 24:08seems like we have little information
  572. 24:10here, but thinking in terms of
  573. 24:11differential diagnosis, this is the
  574. 24:13face of Takayasu's. So, for this UFRJ
  575. 24:15question, it's difficult, okay? We have
  576. 24:18to remember Takayasu's arteritis. All
  577. 24:20the others do not justify this
  578. 24:22peripheral involvement with absence or
  579. 24:24reduction of pulse. They could justify
  580. 24:27a stroke, but not this involvement of
  581. 24:29peripheral pulses. All good? Now then
  582. 24:32we move from Takayasu's to giant cell
  583. 24:34arteritis, which as I mentioned is the
  584. 24:37large vessel vasculitis of the elderly.
  585. 24:40So here the epidemiology is key. These
  586. 24:44are adults aged 50 and older, but the
  587. 24:46older they are, the higher the chance,
  588. 24:48generally of Caucasian ethnicity, this
  589. 24:50is also classic, and it also affects
  590. 24:51more women, just like Takayasu's, okay?
  591. 24:55Regarding giant cell arteritis, it
  592. 24:57involves the aorta and large vessels,
  593. 24:59yes, but it has a different profile. In
  594. 25:01Takayasu, there is a predominance of
  595. 25:03the aortic arch. Here, what we see is a
  596. 25:05predominance of the vertebral artery
  597. 25:08and its extracranial branches. Actually
  598. 25:10, the vertebral artery and the
  599. 25:12extracranial branches of the carotid.
  600. 25:14And among these extracranial carotid
  601. 25:16branches, there is a favorite, which is
  602. 25:19? The temporal artery, which is here,
  603. 25:22and it brings a very characteristic
  604. 25:24finding of the disease. Got it? About
  605. 25:27the epidemiology, it's what I mentioned
  606. 25:29initially; you have to memorize it
  607. 25:30because it helps a lot in the
  608. 25:32differential diagnosis. And regarding
  609. 25:34the clinical picture, that
  610. 25:36constitutional frame I mentioned for
  611. 25:38Takayasu can also be present here, but
  612. 25:40what will initially draw attention to
  613. 25:42the diagnosis of giant cell arteritis
  614. 25:44or temporal arteritis is a new headache
  615. 25:46. So, if you see a patient over 50 with
  616. 25:50a new, recent-onset headache that
  617. 25:53doesn't respond to analgesics, think of
  618. 25:55giant cell. Can it be temporal? Of
  619. 25:58course it can, it's the classic
  620. 26:00presentation of the disease, but it can
  621. 26:02also take on other patterns, so stay
  622. 26:05alert; it can be holocranial,
  623. 26:06hemicranial, etc. Among other physical
  624. 26:09exam findings, they will all stem from
  625. 26:11some degree of vessel obstruction. So,
  626. 26:14for example, jaw claudication is
  627. 26:16nothing more than the upper limb
  628. 26:18claudication of Takayasu, just here, in
  629. 26:21the region supplying the jaw. So, as
  630. 26:24the patient chews or speaks, it gets
  631. 26:27tired. The same thing that happens with
  632. 26:30the arm; jaw claudication is highly
  633. 26:32specific to giant cell. And we also
  634. 26:34have the arteritic phenomenon, which
  635. 26:37affects these, the ophthalmic vessels.
  636. 26:39And that is why we have ocular
  637. 26:41complications, typical of the disease.
  638. 26:43It can range from blurred vision and
  639. 26:46double vision to amaurosis fugax. And
  640. 26:49as the most serious and feared event of
  641. 26:52giant cell arteritis, there is
  642. 26:54permanent vision loss, permanent
  643. 26:56blindness, okay? And generally, this
  644. 26:59blindness results from a neuropathy, an
  645. 27:01anterior ischemic optic neuropathy,
  646. 27:04also called AION, okay? So, just to
  647. 27:06remember the mechanism of vision loss
  648. 27:08in these patients. Regarding the
  649. 27:11clinical picture here, it is essential
  650. 27:13that we remember an association. So,
  651. 27:15giant cell is this clinical picture and
  652. 27:17is a systemic vasculitis. However, in
  653. 27:20up to 40-60%of these patients, they may
  654. 27:23present with another disease
  655. 27:25concomitantly with the arteritis. And
  656. 27:28what disease is that? It is polymyalgia
  657. 27:30rheumatica. There’s no way around it,
  658. 27:32you have to memorize it. I joke that
  659. 27:34they are like a musical duo. We’re
  660. 27:36going to have a few" dynamic duos "
  661. 27:38throughout this class, for those times
  662. 27:40when you don't know who's who. So, this
  663. 27:42is to help you remember that
  664. 27:43relationship. Polymyalgia rheumatica is
  665. 27:46not a systemic vasculitis; it is an
  666. 27:48immune-mediated rheumatological disease
  667. 27:50that causes inflammation in structures
  668. 27:53around the joint, periarticular tissues
  669. 27:55, and the joint itself. And in
  670. 27:57polymyalgia rheumatica, we have several
  671. 27:59points in common with arteritis. The
  672. 28:01epidemiology is the same as I discussed
  673. 28:03: patients aged 50 and older. We have a
  674. 28:06clinical picture that is highly
  675. 28:08characteristic. You’ll see it in exam
  676. 28:12questions: it’s pain, stiffness, and
  677. 28:14limitation in the shoulder girdle and
  678. 28:17pelvic girdle, the hip region, okay? So
  679. 28:21, do you see any patient over 50 with
  680. 28:24this clinical picture? Usually
  681. 28:26developing over a few weeks, subacutely
  682. 28:28, think of polymyalgia rheumatica, and
  683. 28:30it can occur alone or accompanied by
  684. 28:32giant cell arteritis, okay? These are
  685. 28:35diseases that exist separately, but can
  686. 28:36appear together, okay? You have to
  687. 28:39memorize this association. So,
  688. 28:40regarding the clinical picture of
  689. 28:42polymyalgia, to help you remember, this
  690. 28:44shoulder girdle involvement can even
  691. 28:46cause complaints here, in the occipital
  692. 28:48and cervical regions. And the
  693. 28:50involvement of the pelvic region, the
  694. 28:52hip area, can even lead to complaints
  695. 28:54of lower back pain, okay? So, burn this
  696. 28:57image into your mind to remember
  697. 28:58polymyalgia. Regarding complementary
  698. 29:02exam findings, basically lab tests, the
  699. 29:04same ones apply to both arteritis and
  700. 29:06polymyalgia. Anemia of chronic disease,
  701. 29:09sometimes thrombocytosis. But remember
  702. 29:12that these are two of the diseases in
  703. 29:15medicine that most frequently present
  704. 29:18with elevated ESR, and significantly
  705. 29:21elevated CRP, but most
  706. 29:23characteristically the ESR. So here, we
  707. 29:27will have values above 50 in the vast
  708. 29:30majority of cases, and in some, it will
  709. 29:33approach or even exceed 100 mm in the
  710. 29:35first hour, okay? So remember, if you
  711. 29:38see the typical clinical picture of one
  712. 29:41or both with a high ESR, you should
  713. 29:43think of these diseases, okay?
  714. 29:45Regarding imaging for giant cell
  715. 29:47arteritis. We can use arteriography, MR
  716. 29:50angiography, CT angiography, or even
  717. 29:53PET-CT, which is the image we see here,
  718. 29:56where there is high uptake in the
  719. 29:59thoracic and abdominal aorta. But one
  720. 30:03test that has been gaining popularity
  721. 30:05and appearing on exams, because it is
  722. 30:07low-cost, easily performed, allows for
  723. 30:09an immediate report, and when done by a
  724. 30:11trained professional, is excellent and
  725. 30:14highly accurate for giant cell
  726. 30:15arteritis, is the ultrasound of the
  727. 30:17arteries: the temporal and axillary
  728. 30:20arteries. In general, those are the
  729. 30:22ones we do most, okay? So, in terms of
  730. 30:25diagnostic workup and imaging exams,
  731. 30:27these are basically what we can rely on
  732. 30:29. Now, if we are thinking in terms of
  733. 30:32the gold standard, what is desirable in
  734. 30:35every case would be a biopsy. Biopsy of
  735. 30:38what? Of the temporal artery. But we
  736. 30:41have a few issues. This biopsy is not
  737. 30:44widely available, generally only in
  738. 30:46large centers, right? It must be
  739. 30:48performed very well because the
  740. 30:49inflammatory involvement in giant cell
  741. 30:51arteritis is skip-lesional. So, if you
  742. 30:54take a fragment from just one region,
  743. 30:56it may come back without any
  744. 30:58abnormalities, and you might miss a
  745. 31:00diagnosis if you rely solely on that
  746. 31:02pathology report, okay? So, this
  747. 31:04skip-lesional involvement is a classic
  748. 31:06feature, which is why several samples
  749. 31:07must be collected. And one last
  750. 31:09important piece of information is: do
  751. 31:11not delay treatment for giant cell
  752. 31:13arteritis while waiting for a biopsy.
  753. 31:16It can be done even after a few weeks
  754. 31:18of using the key drug for managing this
  755. 31:20disease. And the drug that treats this
  756. 31:24systemic vasculitis, make no mistake,
  757. 31:26is the glucocorticoid. Generally high
  758. 31:29doses, as we do in Takayasu's, at 1 mg/
  759. 31:32kg per day. In some cases, we might
  760. 31:35even have to consider pulse therapy
  761. 31:37with methylprednisolone, for example,
  762. 31:39if I am considering ischemic optic
  763. 31:42neuropathy, but it is
  764. 31:43corticosteroid-based; for refractory
  765. 31:45cases, you already know we will use a
  766. 31:48synthetic immunosuppressant or a
  767. 31:50biological immunosuppressant in cases
  768. 31:52refractory to synthetic ones. Got it?
  769. 31:55Regarding polymyalgia rheumatica, it is
  770. 31:57also treated with corticosteroids and
  771. 31:59is closely related to giant cell
  772. 32:00arteritis. But in polymyalgia, there is
  773. 32:02an interesting detail: the patient uses
  774. 32:04low to moderate doses of prednisone. So
  775. 32:06, generally 10 mg, 15 mg. And then they
  776. 32:10have a great clinical and laboratory
  777. 32:12response, a rapid response, okay? So
  778. 32:15remember this detail because the doses
  779. 32:16are very different for polymyalgia and
  780. 32:18for giant cell arteritis. Questions for
  781. 32:20us to reinforce. The first one from
  782. 32:23Santa Casa de Misericórdia de São
  783. 32:24Paulo. A 64-year-old woman, previously
  784. 32:27healthy, presents with a one-month
  785. 32:29history of intense headache that does
  786. 32:31not respond to analgesics. In addition,
  787. 32:35systemic symptoms with a low-grade
  788. 32:36fever almost daily. They performed a
  789. 32:39biopsy, and based on this biopsy, they
  790. 32:42made a diagnosis of giant cell
  791. 32:44arteritis. And then it asks, among the
  792. 32:47statements below, it wants the
  793. 32:49incorrect one, the one we cannot relate
  794. 32:52to giant cell arteritis. Let's go.
  795. 32:55Anemia and fever of unknown origin have
  796. 32:58everything to do with giant cell
  797. 33:00arteritis, a systemic vasculitis that
  798. 33:02inflames the patient as a whole. It is
  799. 33:06indeed a cause of fever of unknown
  800. 33:08origin in elderly patients. So, it is
  801. 33:10correct; therefore, we cannot mark it.
  802. 33:13B. Cause of sudden monocular vision
  803. 33:16loss. Exactly. It is what we were
  804. 33:19discussing previously, including this
  805. 33:21mechanism of NAION, okay? So no, this
  806. 33:23is a highly feared complication of the
  807. 33:25disease. We cannot mark it. C. Almost
  808. 33:28exclusive involvement in patients over
  809. 33:3150 years old. This is a classic feature
  810. 33:33of this vasculitis. Under no
  811. 33:35circumstances can we mark this
  812. 33:36alternative, because this is the
  813. 33:38classic of classics. In D, it mentions
  814. 33:41jaw claudication. And I told you that
  815. 33:43this is a highly specific finding of
  816. 33:45giant cell arteritis. So we cannot mark
  817. 33:48it. Let's see if the error is in E,
  818. 33:50inflammation restricted to arteries
  819. 33:52originating from the aortic arch. And
  820. 33:54this is where the error is, because not
  821. 33:57only the arteries that exit the aortic
  822. 33:59arch are affected in giant cell
  823. 34:00arteritis. I told you that this applied
  824. 34:02mainly to Takayasu. Here we can have
  825. 34:04involvement of the thoracic aorta and
  826. 34:06other segments, and involvement of the
  827. 34:08thoracic aorta can even generate
  828. 34:10aneurysmal dilation in this thoracic
  829. 34:12aorta over time. So, E is incorrect
  830. 34:15because of this detail, but if you were
  831. 34:17sharp, all the others could be
  832. 34:19classified as correct based on this
  833. 34:21knowledge we just had about the
  834. 34:23vasculitis, okay? So, the answer key is
  835. 34:27letter E. And there is one more
  836. 34:29question, oops, about the two diseases,
  837. 34:31giant cell arteritis and polymyalgia, a
  838. 34:34good question from UNIFESP, which I put
  839. 34:36here for you to really fix this image,
  840. 34:39okay? Let's go. Look at the
  841. 34:41epidemiology. An elderly woman, 75
  842. 34:43years old, presenting with pain,
  843. 34:46limited movement, and morning stiffness
  844. 34:48. And where? In the shoulders and hips
  845. 34:52for a month. A subacute picture that
  846. 34:55looks just like polymyalgia rheumatica.
  847. 34:59It's not improving with dipyrone, and I
  848. 35:01know it won't because it will only
  849. 35:02improve with corticosteroids. Besides
  850. 35:04that, she has a low-grade fever, loss
  851. 35:06of appetite, and in the investigation,
  852. 35:07findings of inflammation, right?
  853. 35:09Normocytic, normochromic anemia. Look
  854. 35:11at this highly increased ESR, the face
  855. 35:14of polymyalgia, CRP as well. But what
  856. 35:17clinches this question and this dual
  857. 35:19diagnosis is the PET scan. What did the
  858. 35:22PET/CT show? Intense uptake in both the
  859. 35:25thoracic aorta and the abdominal aorta.
  860. 35:30It also picked up in other regions,
  861. 35:31look, axillary arteries, which I said
  862. 35:33were an interesting site currently
  863. 35:35evaluated for giant cell arteritis, and
  864. 35:37also in the polymyalgia region,
  865. 35:39shoulders and hips. Look, very likely
  866. 35:42this PET scan had an image very similar
  867. 35:45to this one I showed you. So now we
  868. 35:47know there is a characteristic clinical
  869. 35:49presentation of polymyalgia rheumatica.
  870. 35:52Let me go back to the question here.
  871. 35:54But this large vessel involvement is
  872. 35:56not from polymyalgia. It is not a
  873. 35:57vasculitis. Who is it that causes this
  874. 35:59and that can be associated with
  875. 36:01polymyalgia? It is giant cell arteritis
  876. 36:03. Therefore, the answer to this
  877. 36:05question is letter A. Okay? Thus, we
  878. 36:07finish large vessels and move on to
  879. 36:10medium vessels, for which we have a
  880. 36:12representative, polyarteritis nodosa.
  881. 36:15So, regarding polyarteritis nodosa, you
  882. 36:17will begin to notice that as I progress
  883. 36:20here through the vasculitides, we will
  884. 36:22automatically notice a greater variety
  885. 36:24of clinical manifestations, because we
  886. 36:27will have more vessels affected. So, in
  887. 36:30the case of polyarteritis nodosa, we
  888. 36:33have a vasculitis that will mainly
  889. 36:35affect the skin, nerves, and viscera.
  890. 36:38That is why I have visceral
  891. 36:39manifestations, okay? It is a
  892. 36:41vasculitis with necrotizing
  893. 36:42characteristics and the epidemiology
  894. 36:44also changes. There it was mostly women
  895. 36:46, right? Now it is men. Basically the
  896. 36:48majority are men, and middle-aged men.
  897. 36:52And just as I spoke about the" dynamic
  898. 36:55duo, "right, of giant cell arteritis
  899. 36:57and polymyalgia rheumatica, to start
  900. 36:59polyarteritis nodosa, you must already
  901. 37:01remember this textbook association that
  902. 37:03is heavily explored in exams, which is
  903. 37:06the relationship between polyarteritis
  904. 37:08nodosa and hepatitis B. To memorize it,
  905. 37:10remember, polyarteritis nodosa with the
  906. 37:13B from hepatitis B. Got it? I think
  907. 37:16that makes it easier. Of course, today
  908. 37:18with the mass vaccination we have,
  909. 37:19especially here in Brazil, this is
  910. 37:21actually becoming less and less
  911. 37:22frequent. But for your exam, it is a
  912. 37:24great tip. Serology compatible with
  913. 37:28hepatitis B, eventually they put there,
  914. 37:30right, viral DNA compatible with the B
  915. 37:32virus, they present a patient who has
  916. 37:34chronic liver disease and a clinical
  917. 37:36picture of polyarteritis; think about
  918. 37:38this association. So, memorize it from
  919. 37:41now on, okay? The second" dynamic duo "
  920. 37:43of our class. Now, thinking about
  921. 37:46polyarteritis nodosa, clinical
  922. 37:47presentation. Besides the general
  923. 37:50clinical picture, that constitutional
  924. 37:51one we discussed, I have more clinical
  925. 37:53manifestations and in polyarteritis
  926. 37:55there isn't one that clinches the
  927. 37:57diagnosis. We will generally find
  928. 37:59several of them in association in the
  929. 38:01question statement. Let's start with
  930. 38:03the most frequent one, which is
  931. 38:04peripheral nervous system involvement,
  932. 38:06generally in the form of mononeuritis
  933. 38:07multiplex. Varied skin lesions, from
  934. 38:10subcutaneous nodules to purpuric
  935. 38:12lesions of small-vessel vasculitis.
  936. 38:15However, we can also have a more
  937. 38:18dramatic evolution with actual necrosis
  938. 38:20, gangrene, ischemia of the extremities
  939. 38:23, and I may have livedo, generally
  940. 38:25livedo here, see, as this is a livedo
  941. 38:27reticularis. Regarding renal
  942. 38:30involvement, we do not have
  943. 38:32glomerulonephritis. I will highlight
  944. 38:34this in a moment. What we see here is a
  945. 38:36vascular nephropathy. So I have
  946. 38:39elevated blood pressure levels, I have
  947. 38:41mild proteinuria, I have elevated urea
  948. 38:44and creatinine, but I don't have, for
  949. 38:46example, dysmorphic hematuria, I don't
  950. 38:48have nephrotic-range proteinuria, none
  951. 38:51of that. Here the involvement is
  952. 38:53vascular, not of the glomerulus.
  953. 38:56Regarding the abdomen, we can have
  954. 38:58mesenteric angina due to involvement of
  955. 39:00mesenteric vessels. We can have a
  956. 39:03classic symptom of this vasculitis,
  957. 39:05which is testicular pain; both in exams
  958. 39:08and in real life, it doesn't appear in
  959. 39:10most patients, okay? But when an exam
  960. 39:12question presents a man with testicular
  961. 39:15pain, with orchitis, and who has these
  962. 39:17other findings, you should think of
  963. 39:19polyarteritis nodosa, okay? And finally
  964. 39:21, it is also a cause of cardiomyopathy,
  965. 39:23both direct, right? It is caused, for
  966. 39:26example, by coronary changes, as well
  967. 39:28as secondary to this vascular
  968. 39:29nephropathy. So this is the face of PAN
  969. 39:32, and this slide here will help a lot
  970. 39:34in the differential diagnosis of this
  971. 39:36vasculitis with the small-vessel ones
  972. 39:38that we will discuss shortly. First
  973. 39:41point, I just said it, polyarteritis
  974. 39:43nodosa is not a cause of
  975. 39:44glomerulonephritis. So that already
  976. 39:47helps a lot. But another point that
  977. 39:50will be fundamental is the fact that in
  978. 39:52polyarteritis nodosa I did not mention
  979. 39:54involvement of the respiratory tract,
  980. 39:57neither upper nor lower, right? Neither
  981. 40:00upper nor lower airways, it's because
  982. 40:02polyarteritis nodosa spares the lungs,
  983. 40:04spares the airways, okay? So we don't
  984. 40:07find this in this vasculitis, okay?
  985. 40:11Regarding laboratory findings, folks,
  986. 40:13nothing specific. High CRP and ESR,
  987. 40:15anemia. Remember that here we have to
  988. 40:18investigate hepatitis B? And if I think
  989. 40:21in terms of biopsy, here it is also
  990. 40:23desirable. Whenever we can perform a
  991. 40:26biopsy of skin, nerve, or testicle, or
  992. 40:28muscle, we will do it. And then what do
  993. 40:31we find? A necrotizing vasculitis, okay
  994. 40:34? This is the hallmark of this disease.
  995. 40:37And regarding imaging, remember what I
  996. 40:39mentioned about vasculitis; in general,
  997. 40:41we see stenotic segments, narrowing of
  998. 40:44the vessel lumen alternating with areas
  999. 40:46of aneurysmal dilation. In the case of
  1000. 40:49polyarteritis nodosa, this is very well
  1001. 40:52defined, as the arrows show here, but
  1002. 40:54they are microaneurysms, these are very
  1003. 40:57small areas, see, that form in an
  1004. 40:59alternating pattern. Here I have an
  1005. 41:01area of ischemia, there is no blood
  1006. 41:03flow, and in this one, we have a small
  1007. 41:05aneurysm, a microaneurysm; this has
  1008. 41:06already appeared on exam questions,
  1009. 41:08okay? So, an angiography, for example,
  1010. 41:11or an MRA of the mesentery, mesenteric
  1011. 41:14vessels, abdomen, or even renal vessels
  1012. 41:16showing this finding. So, you have to
  1013. 41:18remember that. And finally, treatment.
  1014. 41:20Do you have any questions? It’s
  1015. 41:22corticosteroids, guys. Variable doses,
  1016. 41:23generally high doses, okay? 0.5 mg per
  1017. 41:26kg/day, 1 mg per kg/day, it depends on
  1018. 41:28the involvement. And don't forget, we
  1019. 41:30must always investigate for Hepatitis
  1020. 41:32B. This is mandatory if the prompt
  1021. 41:34hasn't already given it to you.
  1022. 41:36Sometimes an exam question wants you to
  1023. 41:39actually request or identify a test
  1024. 41:41expected in the context of this disease
  1025. 41:43, and it generally involves serology,
  1026. 41:45investigating Hepatitis B. Now, let's
  1027. 41:48look at questions to remember the look
  1028. 41:50of the disease. A 36-year-old man with
  1029. 41:53acute testicular pain for 48 hours.
  1030. 41:56Could it be a surgery case, a
  1031. 41:57testicular torsion? No, it is not. In
  1032. 42:00this case, he currently has testicular
  1033. 42:03pain, but for two months he has had
  1034. 42:05involuntary weight loss, a significant
  1035. 42:07loss of 6 kg, paresthesia in his hands
  1036. 42:10and feet, peripheral neurological
  1037. 42:12involvement, and livedo reticularis. On
  1038. 42:15physical exam, elevated blood pressure.
  1039. 42:19And then it says:" Given the suspicion
  1040. 42:21of systemic vasculitis, come back to me
  1041. 42:22. Systemic vasculitis that affects
  1042. 42:26mostly adult men, presenting with
  1043. 42:28testicular pain, peripheral
  1044. 42:30neurological involvement, and skin
  1045. 42:32lesions. What vasculitis is this? It is
  1046. 42:36polyarteritis nodosa. And it wants to
  1047. 42:38know—this is a great question—what
  1048. 42:40complementary exam finding is
  1049. 42:42compatible with polyarteritis nodosa.
  1050. 42:44In A, request a 24-hour proteinuria to
  1051. 42:46help with the differential diagnosis
  1052. 42:49here. I told you, vascular nephropathy,
  1053. 42:51if it presents with protein, it's mild
  1054. 42:54proteinuria; it's not massive, so it
  1055. 42:56won't help much here. B. Chest CT
  1056. 42:59angiography. No. Remember that
  1057. 43:01polyarteritis nodosa spares the airways
  1058. 43:04. I won't see anything in the chest
  1059. 43:06region for this patient. C. Evaluation
  1060. 43:09of erythrocyte dysmorphism. Another
  1061. 43:11trick is the cause of vascular
  1062. 43:13nephropathy, not glomerulonephritis,
  1063. 43:15which presents with dysmorphic
  1064. 43:17hematuria. So, C is out regarding
  1065. 43:20cryoglobulin measurement. We will see
  1066. 43:22the disease where this is important
  1067. 43:24soon, but it’s not in polyarteritis.
  1068. 43:26And we arrive at E, which says to
  1069. 43:28request an abdominal angiography, and
  1070. 43:30we will look for that finding, right,
  1071. 43:32of alternating stenoses and
  1072. 43:34microaneurysms. Got it? Typical of
  1073. 43:36polyarteritis nodosa. And the next one,
  1074. 43:39which is basically a review of this
  1075. 43:40vasculitis, a very cool question. What
  1076. 43:43is correct to state about polyarteritis
  1077. 43:45nodosa? A, it is a necrotizing,
  1078. 43:47multisystemic vasculitis, so far
  1079. 43:49correct, that affects small and
  1080. 43:51medium-sized muscular arteries, is that
  1081. 43:53right? Okay? It is predominantly
  1082. 43:55medium-sized, but it can also affect
  1083. 43:57small ones. But the problem is at the
  1084. 44:00end, where involvement of pulmonary
  1085. 44:02arteries is characteristic. That is
  1086. 44:05exactly what polyarteritis nodosa does
  1087. 44:07not do. B. Is the kidney pathology
  1088. 44:10arteritis with glomerulonephritis? No,
  1089. 44:13folks, it is an arteritis that leads to
  1090. 44:16vascular nephropathy, B is out. C.
  1091. 44:19Nonspecific signs and symptoms are an
  1092. 44:21essential characteristic, they are
  1093. 44:23important, but "essential" is strong,
  1094. 44:25right? Because they are not specific to
  1095. 44:27any disease. And then they say that
  1096. 44:29fever, weight loss, and general malaise
  1097. 44:31are present in more than half of the
  1098. 44:33cases. And that is correct. So, all
  1099. 44:36these vasculitides can present with
  1100. 44:38systemic signs and symptoms, okay? It
  1101. 44:41is not that it is essential for the
  1102. 44:43diagnosis, but in fact, compared to
  1103. 44:46others, in polyarteritis nodosa we
  1104. 44:48notice a much higher frequency of fever
  1105. 44:51, weight loss, and asthenia compared to
  1106. 44:53the others. Got it? So, in this context
  1107. 44:56, I think we can consider C correct,
  1108. 44:58yes. In D, diagnostic serological tests
  1109. 45:01are essential for the diagnosis. And
  1110. 45:03here I have to order ANCA antibody,
  1111. 45:05either against myeloperoxidase or
  1112. 45:06proteinase 3. It is precisely this type
  1113. 45:09of vasculitis that we will discuss next
  1114. 45:12, it is not polyarteritis; the
  1115. 45:13prognosis of the disease, even without
  1116. 45:16treatment, is extremely positive, with
  1117. 45:18a 10-year survival rate of 90 to 100%.
  1118. 45:21A more difficult question, because this
  1119. 45:23is a detail that in general we don't
  1120. 45:24see directly in the process, that’s
  1121. 45:26for clinical residents, okay? But I
  1122. 45:27will tell you in advance, actually, the
  1123. 45:29prognosis of the disease is not good.
  1124. 45:31It is associated with high morbidity
  1125. 45:33and mortality, especially if the
  1126. 45:34diagnosis is not made quickly. So here
  1127. 45:37we do not have a disease with a
  1128. 45:39positive prognosis and the survival
  1129. 45:42rate is well below 90-100%at 10 years,
  1130. 45:44okay? So it is a potentially quite
  1131. 45:46serious vasculitis. I told you, we
  1132. 45:48start treatment with a high-dose
  1133. 45:49corticosteroid right away. So, since
  1134. 45:51the question asks for the correct
  1135. 45:53alternative, it's indeed C, which
  1136. 45:55mentions these non-specific systemic
  1137. 45:57signs and symptoms, but they are quite
  1138. 45:59prominent here in polyarteritis nodosa,
  1139. 46:02alright? So, that wraps up medium-sized
  1140. 46:04vessels; remember Kawasaki will be
  1141. 46:06discussed in pediatrics, and we’ll
  1142. 46:08move into the group of diseases with
  1143. 46:10the largest number of representatives:
  1144. 46:12small-vessel vasculitis. And here we
  1145. 46:14have two groups, remember? Those
  1146. 46:16associated with ANCA and those
  1147. 46:18associated with immune complex
  1148. 46:20deposition. Let's start with ANCA. Here
  1149. 46:23we must first remember that ANCA is not
  1150. 46:26a specific antibody. It is actually a
  1151. 46:30generic name for several antibodies
  1152. 46:32formed against the neutrophil cytoplasm
  1153. 46:35. They can be present in various
  1154. 46:39rheumatological and non-rheumatological
  1155. 46:42diseases, but there is a group of
  1156. 46:44diseases where this ANCA plays an
  1157. 46:47important pathophysiological role. In
  1158. 46:51these diseases, it shows a high
  1159. 46:53positivity rate, a high percentage of
  1160. 46:56patients, which differs from other
  1161. 46:58diseases where it appears
  1162. 47:00non-specifically, much like what we see
  1163. 47:02with rheumatoid factor or ANA. So, in
  1164. 47:06rheumatology, we need to demystify some
  1165. 47:08concepts. Obviously, ANCA has a very
  1166. 47:10strong association with the diseases we
  1167. 47:12will discuss from now on, but it is not
  1168. 47:13specific to them, okay? It can appear
  1169. 47:16in various other contexts. Now, when we
  1170. 47:19think about the diseases where ANCA is
  1171. 47:22characteristically present, some
  1172. 47:24similarities appear regarding these
  1173. 47:26conditions, okay? Basically, they are
  1174. 47:30small-vessel vasculitides, necrotizing
  1175. 47:33vasculitides, and memorize this:
  1176. 47:36vasculitides in which there is little
  1177. 47:39to no immune deposit. Why is this
  1178. 47:42important? Sometimes a test question
  1179. 47:44will use a biopsy as the key to the
  1180. 47:46solution. A lung biopsy or a kidney
  1181. 47:49biopsy; every time you find, for
  1182. 47:51example, pauci-immune
  1183. 47:52glomerulonephritis, it should
  1184. 47:54immediately remind you of
  1185. 47:55ANCA-associated vasculitis, okay? So
  1186. 47:59that is basically what unites these
  1187. 48:01three vasculitides here, just like the
  1188. 48:03caliber of the vessels predominantly
  1189. 48:05affected, which I told you to memorize,
  1190. 48:07you must memorize these too. There are
  1191. 48:09three. So let's go. The most famous one
  1192. 48:12that appears most often on the exam:
  1193. 48:14Wegener's granulomatosis or
  1194. 48:15granulomatosis with polyangiitis, which
  1195. 48:17is the term most currently used.
  1196. 48:19Microscopic polyangiitis, which is rare
  1197. 48:22in real life and extremely rare in
  1198. 48:24direct entry exams. And Churg-Strauss
  1199. 48:26syndrome, or eosinophilic
  1200. 48:28granulomatosis with polyangiitis, which
  1201. 48:30, right there after Wegener's, is the
  1202. 48:32one that appears the most, okay? So,
  1203. 48:35let's start with the one that is
  1204. 48:37generally the favorite of this group,
  1205. 48:39which is granulomatosis with
  1206. 48:41polyangiitis. All of them, guys, affect
  1207. 48:44adult men and women of any age group,
  1208. 48:46okay? So, there's nothing
  1209. 48:48characteristic about this, and what
  1210. 48:50will draw attention in all these
  1211. 48:52vasculitides initially are one or more
  1212. 48:54systemic signs or symptoms, just like
  1213. 48:56we've been discussing until now. But
  1214. 48:59for you to think of Wegener's, look in
  1215. 49:02the statement for at least two or maybe
  1216. 49:04three components of this triad that I'm
  1217. 49:06going to tell you about right now, okay
  1218. 49:08? All the small-vessel vasculitides
  1219. 49:12we're going to discuss from here on are
  1220. 49:14associated with dozens of clinical
  1221. 49:16manifestations, because think, with
  1222. 49:18small vessels, we have to understand
  1223. 49:20capillaries, arterioles, and venules.
  1224. 49:23And we have those basically all over
  1225. 49:26the body. So, any organ or system can
  1226. 49:28be affected in these vasculitides. So,
  1227. 49:31so we don't get lost in manifestations
  1228. 49:33that aren't typical for each one,
  1229. 49:35memorize the ones that are
  1230. 49:37characteristic of each, okay? And in
  1231. 49:40the case of Wegener's, the triad is
  1232. 49:41formed by the involvement of the upper
  1233. 49:44airways. And I'll show you with what?
  1234. 49:46Lower airways and added to that, renal
  1235. 49:49involvement in the form of
  1236. 49:51glomerulonephritis. In the upper
  1237. 49:54airways. What stands out in Wegener's?
  1238. 49:57A chronic condition of sinus disease,
  1239. 49:59rhinosinusitis, a recurring thing that
  1240. 50:01doesn't improve with the use of
  1241. 50:03antibiotics, okay? This is
  1242. 50:05characteristic of Wegener's and can
  1243. 50:07cause rhinorrhea, purulent rhinorrhea,
  1244. 50:09and eventually epistaxis. It is a cause
  1245. 50:11of saddle nose. The inflammatory
  1246. 50:14process can eat away at the cartilage,
  1247. 50:16and then we are left with that saddle
  1248. 50:17nose, which can also be seen, for
  1249. 50:19example, in patients who use cocaine.
  1250. 50:22So, upper airways are present in most
  1251. 50:24patients with Wegener's, okay?
  1252. 50:27Descending to the lower airways, we can
  1253. 50:29have nodules, pulmonary nodules that
  1254. 50:31cavitate, like these here, or pulmonary
  1255. 50:34nodules that don't cavitate, like some
  1256. 50:36others we see on this X-ray. Here is
  1257. 50:40the saddle nose I mentioned earlier,
  1258. 50:42but still in the lung, we can also find
  1259. 50:45alveolar hemorrhage of varying degrees,
  1260. 50:48okay? Even leading to a severe acute
  1261. 50:51respiratory syndrome with diffuse
  1262. 50:54bilateral infiltrates. In the kidneys,
  1263. 50:56I've already dropped the hint: it's
  1264. 50:58glomerulonephritis. All ANCA-associated
  1265. 51:00vasculitides can cause
  1266. 51:02glomerulonephritis. And in general, it
  1267. 51:04is a rapidly progressive
  1268. 51:06glomerulonephritis. So you will see a
  1269. 51:08case of nephritic syndrome. And in this
  1270. 51:10context, we remind you that in the case
  1271. 51:13of these vasculitides, there may or may
  1272. 51:15not be crescents, okay? So you can have
  1273. 51:18rapidly progressive glomerulonephritis,
  1274. 51:21crescentic or non-crescentic, and
  1275. 51:22remember the biopsy finding with little
  1276. 51:25or no immune deposits, pauci-immune.
  1277. 51:27That helps a lot. But among other
  1278. 51:31Wegener's manifestations that have
  1279. 51:33already appeared on exams, remember
  1280. 51:35that systemic disease usually causes
  1281. 51:37joint complaints, skin lesions, mainly
  1282. 51:39due to small vessel vasculitis, so
  1283. 51:41purpura, ulcers. Wegener's loves eyes
  1284. 51:45and ears. So, Wegener's causes
  1285. 51:48scleritis, episcleritis, and orbital
  1286. 51:50pseudotumor causing ocular proptosis.
  1287. 51:54It is a cause of hearing loss or even
  1288. 51:56complete hearing loss. So, Wegener's
  1289. 52:00really likes this face, head, neck, and
  1290. 52:01sinus region, you know. Furthermore, it
  1291. 52:05is also a cause of peripheral
  1292. 52:06neuropathy, mainly in the form of
  1293. 52:08mononeuritis multiplex. So, all of this
  1294. 52:10can appear in a Wegener's question, but
  1295. 52:12the triad is what will dictate it.
  1296. 52:14Regarding lab findings. All secondary
  1297. 52:17to inflammation. The big highlight goes
  1298. 52:19to whom? To ANCA. And with these
  1299. 52:22vasculitides, it's not enough just to
  1300. 52:24memorize that they are ANCA-associated.
  1301. 52:26You need to know which pattern is
  1302. 52:29expected in each of them. Is it
  1303. 52:31cytoplasmic, which is c-ANCA, or is it
  1304. 52:33perinuclear, which is p-ANCA? And which
  1305. 52:36antibody is associated with each of
  1306. 52:38these patterns, okay? So, to make it
  1307. 52:41easier, let's memorize Wegener's first,
  1308. 52:43because for your exam, consider this
  1309. 52:45pattern and this antibody specific and
  1310. 52:48exclusive to Wegener's. If this is in
  1311. 52:50your exam question, it's Wegener's, you
  1312. 52:52can be sure, okay? Basically, it is the
  1313. 52:55c-ANCA pattern, which is cytoplasmic,
  1314. 52:57and the antibody is anti-PR 3,
  1315. 52:58anti-proteinase 3. This comes up a lot.
  1316. 53:02Either they give it in the prompt, or
  1317. 53:04they ask you to mark the alternative
  1318. 53:05that has these antibodies, because it
  1319. 53:07really is something very classic to the
  1320. 53:08disease, okay? So, remember this slide
  1321. 53:12about treatment; it rarely appears on
  1322. 53:13the exam, but basically, folks, let's
  1323. 53:15first talk about those life-threatening
  1324. 53:17conditions. So, granulomatosis with
  1325. 53:21polyangiitis that causes alveolar
  1326. 53:23hemorrhage, that causes rapidly
  1327. 53:25progressive glomerulonephritis, or that
  1328. 53:27causes both at the same time—a
  1329. 53:29pulmonary-renal syndrome, which is a
  1330. 53:31condition with very high morbidity and
  1331. 53:34mortality in medicine, where we have to
  1332. 53:36act very quickly to contain the
  1333. 53:38inflammatory process. So, if it is
  1334. 53:41granulomatosis with polyangiitis or the
  1335. 53:43next one we are going to discuss, which
  1336. 53:45is microscopic polyangiitis, the
  1337. 53:46treatment is the same if it involves
  1338. 53:48this vital organ involvement, which is
  1339. 53:50pulse therapy. We will proceed with
  1340. 53:53high-dose intravenous corticosteroids
  1341. 53:55combined with immunosuppressive drugs,
  1342. 53:57sorry, which can be either rituximab,
  1343. 53:59which is an immunobiological, or
  1344. 54:01cyclophosphamide. And if you have
  1345. 54:04plasmapheresis at your facility in an
  1346. 54:06exam scenario, it is interesting to
  1347. 54:08include this treatment modality,
  1348. 54:10because it helps patient prognosis
  1349. 54:12immensely, okay? For cases of limited
  1350. 54:15Wegener's, those that are more
  1351. 54:16localized, corticosteroids and
  1352. 54:17immunosuppressants, including
  1353. 54:19methotrexate, a synthetic
  1354. 54:20immunosuppressant, work well, all right
  1355. 54:22? But generally, when it appears on the
  1356. 54:24exam, it involves these serious,
  1357. 54:26life-threatening forms of involvement.
  1358. 54:28Okay? Moving on to questions now, so,
  1359. 54:31to memorize Wegener's. Santa Casa de
  1360. 54:33Misericórdia de Belo Horizonte. An
  1361. 54:35adult or middle-aged man seeks medical
  1362. 54:37attention. Look, after numerous failed
  1363. 54:41attempts to treat chronic sinusitis,
  1364. 54:43you see? Sinusitis that doesn't improve
  1365. 54:46on your exam is a reason to consider
  1366. 54:49Wegener's as one of the possibilities.
  1367. 54:51He progressed to nasal septum
  1368. 54:53destruction, that finding of a saddle
  1369. 54:56nose, the loss of the bridge of the
  1370. 54:58nose I mentioned, it’s right here.
  1371. 55:01And besides that, a cough with
  1372. 55:03hemoptysis. Where is this hemoptysis
  1373. 55:05coming from? It could be from a
  1374. 55:07cavitated nodular lesion, it could be
  1375. 55:09from capillaritis, inflammation of the
  1376. 55:12capillary causing alveolar hemorrhage.
  1377. 55:14So we have to be alert here. And this
  1378. 55:17patient was seen by a doctor who
  1379. 55:19suspected a diagnosis of vasculitis.
  1380. 55:21Quite fair. But now you are able to
  1381. 55:24tell me which vasculitis this is. And
  1382. 55:26he gives you one more piece of data.
  1383. 55:27Actually, he gives you the cherry on
  1384. 55:29top. He says that he performed an ANCA
  1385. 55:31test, antineutrophil cytoplasmic
  1386. 55:33antibodies, and the result came back
  1387. 55:35positive. And here, folks, there is no
  1388. 55:37way to think of another hypothesis.
  1389. 55:40Chronic sinus disease that doesn't
  1390. 55:42improve, associated with a cough with
  1391. 55:45hemoptysis, so upper airways, lower
  1392. 55:47airways, and a positive ANCA. What is
  1393. 55:50the vasculitis that characteristically
  1394. 55:52presents with this? Granulomatosis with
  1395. 55:54polyangiitis, or Wegener's
  1396. 55:56granulomatosis? Okay? The answer is
  1397. 55:58here as letter C. The next one is from
  1398. 56:01Surce. So here we have a 40-year-old
  1399. 56:03woman who for a year has had episodes,
  1400. 56:06look here, again, recurrent episodes of
  1401. 56:08purulent rhinorrhea. But 5 months ago,
  1402. 56:12other things were added: adynamia,
  1403. 56:14weight loss, arthralgia, a systemic,
  1404. 56:16non-specific picture, and two weeks ago
  1405. 56:19, conjunctival hyperemia, some ocular
  1406. 56:22inflammation, and a cough with
  1407. 56:24hemoptysis. On physical examination,
  1408. 56:27it's episcleritis that we have here in
  1409. 56:30the eye, okay? Crackles in the upper
  1410. 56:32third of the right hemithorax. So we
  1411. 56:34have to see what is happening here in
  1412. 56:36this lung. And there is lab-confirmed
  1413. 56:38arthritis. In short, we have anemia,
  1414. 56:41mild leukocytosis, mild thrombocytosis,
  1415. 56:44all pointing to systemic inflammation,
  1416. 56:47a very significant elevation in
  1417. 56:49inflammatory markers, and an elevated
  1418. 56:52creatinine. Of course, if we think of a
  1419. 56:5540-year-old woman, it’s not a huge
  1420. 56:57elevation, but still, we don't expect a
  1421. 56:59creatinine of 1.4 in a 40-year-old
  1422. 57:01woman, right? We have urea that is also
  1423. 57:04elevated, and look at this: there is
  1424. 57:06hematuria and proteinuria in a 24-hour
  1425. 57:08sample. This rheumatoid factor, forget
  1426. 57:11it, it's non-reactive. Look at the CT
  1427. 57:12scan. A cavitated nodule in the upper
  1428. 57:15third of the right hemithorax. So,
  1429. 57:19basically, again, we have a chronic
  1430. 57:21episode of sinus disease, a cavitated
  1431. 57:23nodule causing cough with hemoptysis,
  1432. 57:25and glomerulonephritis occurring. This
  1433. 57:28triad in an adult woman makes us think
  1434. 57:31of whom? Granulomatosis with
  1435. 57:33polyangiitis. But they want the
  1436. 57:35laboratory test result associated with
  1437. 57:37this diagnostic hypothesis here; it’s
  1438. 57:39a cool question. And when we think of
  1439. 57:41Wegener's, or granulomatosis with
  1440. 57:43polyangiitis, who do we remember? The
  1441. 57:45ANCA, in the ANCA pattern. And going
  1442. 57:48beyond the antibody, we expect the
  1443. 57:51anti-PR 3 antibody, anti-proteinase 3.
  1444. 57:55All right? So that concludes Wegener's.
  1445. 57:57I will go very quickly through
  1446. 57:59microscopic polyangiitis, because as I
  1447. 58:01already mentioned, it is rarely the
  1448. 58:04target of such questions in direct
  1449. 58:06entry exams. Basically, what you need
  1450. 58:09to know about microscopic polyangiitis
  1451. 58:11is, first, it is ANCA-associated, this
  1452. 58:12could appear in conceptual questions,
  1453. 58:14and it's like Wegener's, but without
  1454. 58:16the granulomatous manifestations; note,
  1455. 58:18"microscopic polyangiitis," there is no
  1456. 58:19"granulomatosis" in the name. So it is
  1457. 58:23a Wegener's that does not have upper
  1458. 58:25airway involvement, which we discussed,
  1459. 58:27and will not cause granulomatous lung
  1460. 58:29involvement, which is what generates
  1461. 58:31those nodules that may or may not
  1462. 58:33cavitate. So, many things we have in
  1463. 58:35Wegener's will be present in
  1464. 58:37microscopic polyangiitis. Alveolar
  1465. 58:39hemorrhage, mononeuritis multiplex,
  1466. 58:41peripheral neurological involvement,
  1467. 58:43the presence of skin lesions like
  1468. 58:45cutaneous vasculitis, and rapidly
  1469. 58:47progressive glomerulonephritis. So much
  1470. 58:50so that microscopic polyangiitis,
  1471. 58:52according to most sources, is the main
  1472. 58:55cause of pulmonary-renal syndrome. Here
  1473. 58:57, in this radiograph, we have a diffuse
  1474. 58:59bilateral infiltrate from a patient
  1475. 59:01with severe alveolar hemorrhage, okay?
  1476. 59:04So, when we think of pulmonary-renal
  1477. 59:06syndrome, various diseases can cause it
  1478. 59:08. I have already shown Wegener's, but
  1479. 59:10in principle, microscopic polyangiitis
  1480. 59:12is the one with the strongest
  1481. 59:13association. Basically, pulmonary
  1482. 59:15capillaritis and rapidly progressive
  1483. 59:17glomerulonephritis happen at the same
  1484. 59:19time here, okay? But in the disease,
  1485. 59:21they can also happen in isolation,
  1486. 59:23nothing prevents it. If I said that
  1487. 59:26c-ANCA and PR3 were exclusive to
  1488. 59:28Wegener's, for microscopic polyangiitis
  1489. 59:30and Churg-Strauss syndrome,
  1490. 59:32eosinophilic granulomatosis, the
  1491. 59:34pattern is different, the antibody is
  1492. 59:36different, and you have to memorize
  1493. 59:38that too. So here we are going to talk
  1494. 59:42about the p-ANCA pattern, which is
  1495. 59:43perinuclear, and the antibody is
  1496. 59:45anti-MPO, anti-myeloperoxidase.
  1497. 59:49Remember that? Do you remember this
  1498. 59:51slide from the one on Wegener's? And
  1499. 59:52then you'll basically nail the
  1500. 59:54questions that appear on the subject,
  1501. 59:55okay? Treatment. Here we will export
  1502. 59:58what I told you about severe cases of
  1503. 1:00:01granulomatosis with polyangiitis,
  1504. 1:00:03methylprednisolone pulse, some heavy
  1505. 1:00:05immunosuppressant, rituximab,
  1506. 1:00:07cyclophosphamide, and plasmapheresis.
  1507. 1:00:11And it's exactly this that answers this
  1508. 1:00:13question from the Petrópolis medical
  1509. 1:00:15school. Look, for a patient diagnosed
  1510. 1:00:18with a pulmonary-renal syndrome with
  1511. 1:00:21p-ANCA positive, and it even says so,
  1512. 1:00:23the diagnosis of microscopic
  1513. 1:00:25polyangiitis is confirmed, with rapidly
  1514. 1:00:27progressive glomerulonephritis, what do
  1515. 1:00:30I have to do initially to induce
  1516. 1:00:32disease remission? In other words, what
  1517. 1:00:35do I have to do as, like, the first
  1518. 1:00:37call, as the first action to control
  1519. 1:00:39this inflammatory process and keep the
  1520. 1:00:42disease quiet? It's exactly what we saw
  1521. 1:00:44. If it's rapidly progressive
  1522. 1:00:46glomerulonephritis, alveolar hemorrhage
  1523. 1:00:48, we don't have time to waste. What are
  1524. 1:00:51we going to do? We're going to pulse
  1525. 1:00:53this patient with methylprednisolone,
  1526. 1:00:55prescribe either cyclophosphamide or
  1527. 1:00:58rituximab, and indicate plasmapheresis
  1528. 1:01:00if it's available, answer choice B. And
  1529. 1:01:03now we're going to the last
  1530. 1:01:04ANCA-associated vasculitis, which has a
  1531. 1:01:07very characteristic look. You cannot
  1532. 1:01:09fail to recognize it when you glance at
  1533. 1:01:12a question, okay? We are talking about
  1534. 1:01:15Churg-Strauss syndrome, today better
  1535. 1:01:17known as eosinophilic granulomatosis
  1536. 1:01:18with polyangiitis. Think with me here.
  1537. 1:01:22We have granulomatosis with
  1538. 1:01:24polyangiitis, which is Wegener's, plus
  1539. 1:01:26eosinophilia. So it has many
  1540. 1:01:30manifestations in common with Wegener's
  1541. 1:01:32, but what will draw attention here is
  1542. 1:01:34the atopic character, the eosinophilic
  1543. 1:01:36character of the disease, okay? If you
  1544. 1:01:39remember that, you'll be able to nail
  1545. 1:01:41the questions. So, again, we don't have
  1546. 1:01:44anything specific in epidemiology, but
  1547. 1:01:46what draws attention and will justify
  1548. 1:01:48the clinical picture is the presence of
  1549. 1:01:50granulomas, granulomatosis, and also
  1550. 1:01:52the infiltration of organs and tissues
  1551. 1:01:54by eosinophils. So, in this disease, we
  1552. 1:01:58characteristically have a prodromal
  1553. 1:02:00phase with constitutional signs and
  1554. 1:02:02symptoms, but which also involves two
  1555. 1:02:05components of a characteristic triad
  1556. 1:02:07that I will tell you about next. After
  1557. 1:02:10that, the so-called eosinophilic phase
  1558. 1:02:12begins, in which we will have
  1559. 1:02:14manifestations resulting from the
  1560. 1:02:15infiltration of eosinophils into
  1561. 1:02:17various tissues. Until finally, we have
  1562. 1:02:20the vasculitic phase, in which the
  1563. 1:02:22patient may present several of the
  1564. 1:02:23manifestations that we discussed for
  1565. 1:02:25Wegener's, okay? So, just as I said
  1566. 1:02:28there was a triad for you to remember
  1567. 1:02:30Wegener's, we have a triad for you to
  1568. 1:02:32remember Churg-Strauss, eosinophilic
  1569. 1:02:35granulomatosis, okay? So, regardless of
  1570. 1:02:38other clinical manifestations, if you
  1571. 1:02:40identify in your prompt an adult
  1572. 1:02:42patient who presents with asthma. And
  1573. 1:02:45the asthma here is generally either of
  1574. 1:02:47adult onset or it was present in
  1575. 1:02:48childhood but was extremely well
  1576. 1:02:50controlled. And then suddenly it came
  1577. 1:02:53back with a vengeance in adulthood, an
  1578. 1:02:55asthma that tends to be difficult to
  1579. 1:02:57control, refractory to treatment,
  1580. 1:02:59requiring a step-up in its treatment.
  1581. 1:03:02So it is not just any asthma associated
  1582. 1:03:04with this. Atopic manifestations,
  1583. 1:03:08mainly chronic rhinosinusitis, allergic
  1584. 1:03:10rhinitis, nasal polyposis, and along
  1585. 1:03:13with this clinical picture, a
  1586. 1:03:15laboratory test finding that the
  1587. 1:03:17disease's own name already brings:
  1588. 1:03:19eosinophilia. And here you have to stay
  1589. 1:03:23sharp with the prompt. It can give you
  1590. 1:03:26either a percentage, you know, relative
  1591. 1:03:28eosinophilia, or an absolute
  1592. 1:03:30eosinophilia. And in the exam, they
  1593. 1:03:33won't leave any doubt, folks; they will
  1594. 1:03:35put an absurdly high eosinophil value,
  1595. 1:03:37sometimes as close to or even higher
  1596. 1:03:39than, I don't know, lymphocytes, even
  1597. 1:03:41neutrophils, to make it clear that
  1598. 1:03:43there is evident eosinophilia, okay? I
  1599. 1:03:46have seen it in real life and sometimes
  1600. 1:03:48it appears on the exam that eosinophils
  1601. 1:03:50correspond to 15, 10, 15, 20%of the
  1602. 1:03:52total leukocytes, which is a lot when
  1603. 1:03:54thinking about eosinophils, okay? So
  1604. 1:03:56that is the basic stuff about
  1605. 1:03:58eosinophilic granulomatosis. And among
  1606. 1:04:00the other manifestations, both from
  1607. 1:04:02tissue invasion by eosinophils and from
  1608. 1:04:05vasculitis, some draw attention. It is
  1609. 1:04:08the ANCA-associated vasculitis that
  1610. 1:04:09most frequently presents with
  1611. 1:04:11mononeuritis multiplex. All of them can
  1612. 1:04:13, but here it is more common. And in
  1613. 1:04:15your prompt, you may find the presence
  1614. 1:04:17of paresthesia and loss of strength in
  1615. 1:04:20multiple, uh, multiple topographies,
  1616. 1:04:22right? So, sometimes it affects the
  1617. 1:04:24hand, sometimes the foot, it affects
  1618. 1:04:25the hand on one side, the foot on the
  1619. 1:04:27other. In some locations there is a
  1620. 1:04:29sensory deficit, in others there is a
  1621. 1:04:31motor deficit. It is a cause of wrist
  1622. 1:04:33drop, foot drop, okay? So, mononeuritis
  1623. 1:04:35multiplex is present in most patients
  1624. 1:04:37with Churg-Strauss. And furthermore, in
  1625. 1:04:40the lungs, besides asthma, we can have
  1626. 1:04:42nodules that do not cavitate. This
  1627. 1:04:44helps a lot in differentiating it from
  1628. 1:04:45Wegener's, which can cavitate. I can
  1629. 1:04:47have migratory infiltrates. On the skin
  1630. 1:04:51, I can have subcutaneous nodules, skin
  1631. 1:04:53granulomas, but also vasculitis,
  1632. 1:04:55gastroenteritis from eosinophilic
  1633. 1:04:56invasion, myocarditis from eosinophilic
  1634. 1:04:59invasion, and glomerulonephritis. It
  1635. 1:05:02can indeed happen in Churg-Strauss
  1636. 1:05:04syndrome, okay? However, compared to
  1637. 1:05:06the other two, it happens less
  1638. 1:05:08frequently here. So mononeuritis is
  1639. 1:05:10more frequent and glomerulonephritis is
  1640. 1:05:12less so, okay? Regarding the laboratory
  1641. 1:05:15tests, you already know, the main
  1642. 1:05:17finding here is eosinophilia,
  1643. 1:05:19corresponding to more than 100 cells in
  1644. 1:05:21absolute value and more than 10%in
  1645. 1:05:23relative value. We can also find
  1646. 1:05:26elevated IgE. After all, I am talking
  1647. 1:05:29about a disease that is clearly
  1648. 1:05:30associated with atopic phenomena. And
  1649. 1:05:32the ANCA is positive in a smaller
  1650. 1:05:34portion than in the other two, okay?
  1651. 1:05:36But for your exam, it will be positive.
  1652. 1:05:39And it will be in this profile,
  1653. 1:05:41perinuclear pattern, p-ANCA, shared
  1654. 1:05:43with polyangiitis, and the antibody is
  1655. 1:05:45anti-MPO. Treatment, you don't need to
  1656. 1:05:48memorize. Here, just remember
  1657. 1:05:50prednisone and immunosuppressants, the
  1658. 1:05:52dose, whether it will be intravenous or
  1659. 1:05:54oral, depends on the severity, but when
  1660. 1:05:56it appears on the exam, it has appeared
  1661. 1:05:58very few times, it was more about the
  1662. 1:06:00management of a bad lung syndrome, as I
  1663. 1:06:02showed you for eosinophilic
  1664. 1:06:04granulomatosis, no need to worry, okay?
  1665. 1:06:06Let's go, a very cool question from
  1666. 1:06:08CSPE. Here we have an adult man of 40
  1667. 1:06:11years old with a clinical picture, look
  1668. 1:06:14, again, a systemic clinical picture,
  1669. 1:06:16fever and weight loss, with skin
  1670. 1:06:18lesions and intense neuropathic pain.
  1671. 1:06:21You already have systemic involvement
  1672. 1:06:22and involvement of the skin and nerves.
  1673. 1:06:25Furthermore, look at his history,
  1674. 1:06:27asthma and rhinosinusitis for 6 years,
  1675. 1:06:29difficult to control, requiring
  1676. 1:06:31frequent courses of oral
  1677. 1:06:32corticosteroids. Look at that
  1678. 1:06:34refractory clinical picture. On
  1679. 1:06:36physical examination, elevated and
  1680. 1:06:38painful purpuric lesions on the lower
  1681. 1:06:40limbs. This is for us to think about
  1682. 1:06:41small-vessel vasculitis of the skin.
  1683. 1:06:43And the neurological examination,
  1684. 1:06:45mononeuritis multiplex. And so, folks,
  1685. 1:06:47there’s no way around it. A patient
  1686. 1:06:49with chronic asthma and rhinosinusitis
  1687. 1:06:51that is difficult to control who
  1688. 1:06:52develops a systemic clinical picture
  1689. 1:06:54and, associated with this, mononeuritis
  1690. 1:06:56multiplex and cutaneous vasculitis. Who
  1691. 1:06:58do we have to think of? Eosinophilic
  1692. 1:07:00granulomatosis with polyangiitis or
  1693. 1:07:02Churg-Strauss. And the question is cool
  1694. 1:07:05because it asks which exam I do not
  1695. 1:07:07expect to find in eosinophilic
  1696. 1:07:09granulomatosis. Let's go. In A, it
  1697. 1:07:12mentions eosinophilia greater than 1500
  1698. 1:07:14. This is a basic finding for us to
  1699. 1:07:16think about this vasculitis. And it is
  1700. 1:07:18generally, right, a super important
  1701. 1:07:20clue for us to suspect it. In B,
  1702. 1:07:22reduced complement levels. I haven't
  1703. 1:07:26mentioned any vasculitis yet that
  1704. 1:07:28triggers immune complex formation which
  1705. 1:07:31consumes complement. That's the next
  1706. 1:07:33one we're going to discuss. So here, I
  1707. 1:07:36don't expect a reduction in C3 and C4
  1708. 1:07:37complement in any of the vasculitides
  1709. 1:07:39we've discussed so far, okay? B is
  1710. 1:07:42already incorrect. C. I expect it to be
  1711. 1:07:45positive. Certainly the hallmark of the
  1712. 1:07:47disease. D. Chest CT showing pulmonary
  1713. 1:07:51infiltrates and nodules that don't
  1714. 1:07:53cavitate. Classic Churg-Strauss. And
  1715. 1:07:57finally, in E, a skin biopsy showing
  1716. 1:07:58necrotizing vasculitis, typical of
  1717. 1:08:00ANCA-associated vasculitis in general.
  1718. 1:08:03But look here, eosinophilic infiltrate,
  1719. 1:08:05which is the hallmark of eosinophilic
  1720. 1:08:07granulomatosis. So, it's a great
  1721. 1:08:10question that tests basically all of
  1722. 1:08:12our knowledge, everything important
  1723. 1:08:14about eosinophilic granulomatosis with
  1724. 1:08:16polyangiitis, okay? So, that concludes
  1725. 1:08:20the ANCA-associated small vessel
  1726. 1:08:22vasculitides, and we move on to the one
  1727. 1:08:24associated with immune complex
  1728. 1:08:26formation, which is cryoglobulinemic
  1729. 1:08:28vasculitis. What do you need to know in
  1730. 1:08:30terms of concepts? What is a
  1731. 1:08:32cryoglobulin? First thing, a
  1732. 1:08:33cryoglobulin is nothing more than a—
  1733. 1:08:35I'll even pull up the next slide, I
  1734. 1:08:37think it's nicer to look at. A
  1735. 1:08:40cryoglobulin is a protein that will
  1736. 1:08:42form, actually, it will be present in
  1737. 1:08:44the patient's blood, and it will—I
  1738. 1:08:46think the image is further ahead, I'll
  1739. 1:08:49show it. And it will sediment, it will
  1740. 1:08:53deposit at the bottom of the vial, from
  1741. 1:08:56that collected blood when we have low
  1742. 1:08:59temperatures—cryoglobulin, cold—and
  1743. 1:09:02then it dissolves again when the sample
  1744. 1:09:05is heated. So, just so you understand
  1745. 1:09:08the term cryoglobulin. But what catches
  1746. 1:09:10our attention about it? Patients can
  1747. 1:09:12have circulating cryoglobulins,
  1748. 1:09:14cryoglobulinemia, without any clinical
  1749. 1:09:16manifestations. Now, in some cases, the
  1750. 1:09:19presence of these cryoglobulins can
  1751. 1:09:21lead to what? It can lead to the
  1752. 1:09:24formation of immune complexes. And what
  1753. 1:09:26joins these immune complexes? The
  1754. 1:09:30cryoglobulin associated with C3 and C4,
  1755. 1:09:33components of the complement system.
  1756. 1:09:36Got it? So, if you understand that, you
  1757. 1:09:39will understand the laboratory test
  1758. 1:09:41findings of this vasculitis, which are
  1759. 1:09:43very characteristic. Here, folks, it's
  1760. 1:09:45not the clinical presentation that is
  1761. 1:09:47generally the key to solving cryo
  1762. 1:09:49questions, no. Here it's the lab work,
  1763. 1:09:50and I'm going to prove it to you, okay?
  1764. 1:09:52So, just so you understand the look of
  1765. 1:09:54these immune complexes, right, formed
  1766. 1:09:57with cryoglobulins, we basically have
  1767. 1:09:59three classes, okay? The first one
  1768. 1:10:01we'll set aside, because it is
  1769. 1:10:03generally associated with hematological
  1770. 1:10:05neoplasms, monoclonal spikes, and other
  1771. 1:10:07issues. In general, when we see
  1772. 1:10:10cryoglobulinemia in daily practice, it
  1773. 1:10:13is more associated with these two types
  1774. 1:10:15, mainly type two, which is what we
  1775. 1:10:17call mixed cryoglobulinemia, having a
  1776. 1:10:20polyclonal component and a monoclonal
  1777. 1:10:22component. So, related terms you might
  1778. 1:10:26find in your exam questions that mean
  1779. 1:10:28the same thing are cryoglobulinemia,
  1780. 1:10:31mixed cryoglobulinemia syndrome or
  1781. 1:10:33essential mixed cryoglobulinemia, and
  1782. 1:10:36cryoglobulinemic vasculitis. I wanted
  1783. 1:10:39to provide this introduction so you
  1784. 1:10:40won't be surprised if you encounter
  1785. 1:10:42different names. We notice this in exam
  1786. 1:10:44questions, okay? They don't value
  1787. 1:10:46semantics that much, so they put
  1788. 1:10:47everything in the same category. Okay?
  1789. 1:10:50Returning now to what matters, talking
  1790. 1:10:52about cryoglobulinemia, we return to
  1791. 1:10:54our "country music duos." Polyarteritis
  1792. 1:10:57nodosa with 'H' for Hepatitis B, giant
  1793. 1:10:59cell arteritis, and polymyalgia
  1794. 1:11:01rheumatica. And here we have the third
  1795. 1:11:04and last one, which is basically
  1796. 1:11:06cryoglobulinemia with 'C' for Hepatitis
  1797. 1:11:08C. Remember how I told you that the
  1798. 1:11:11association for polyarteritis nodosa
  1799. 1:11:13was falling? Not here. Hepatitis C is
  1800. 1:11:16by far, and I mean by a long shot, the
  1801. 1:11:19main cause of cryoglobulinemia. To this
  1802. 1:11:23day, we don't have a vaccine for
  1803. 1:11:25Hepatitis C. So every question
  1804. 1:11:27involving cryoglobulinemia, as I will
  1805. 1:11:29show you, will either mention it in the
  1806. 1:11:31prompt or bring up some mention of
  1807. 1:11:33Hepatitis C, chronic liver disease, or
  1808. 1:11:35something in that scenario, okay? We
  1809. 1:11:38also have other diseases that cause
  1810. 1:11:40cryoglobulinemia, other infections. So
  1811. 1:11:43here we have bacterial infections,
  1812. 1:11:45viral infections, generally those that
  1813. 1:11:47are indolent, rheumatological diseases
  1814. 1:11:49like Sjögren's syndrome, systemic
  1815. 1:11:51lupus erythematosus, neoplasms, and so
  1816. 1:11:53on. But without a doubt, if you think
  1817. 1:11:56of cryoglobulinemia, it's cryo with 'C'
  1818. 1:11:58for Hepatitis C. This is fundamental,
  1819. 1:12:00okay? Regarding the clinical picture,
  1820. 1:12:03it is very generic. Basically
  1821. 1:12:05everything that can involve small
  1822. 1:12:07vessels. Here we can find
  1823. 1:12:09constitutional signs and symptoms,
  1824. 1:12:12arthralgia more common than arthritis,
  1825. 1:12:14general skin lesions, like this:
  1826. 1:12:16small-vessel vasculitis, palpable
  1827. 1:12:19purpura, but it can also cause ulcers
  1828. 1:12:21and ulcer scars. We can have peripheral
  1829. 1:12:25neurological involvement with
  1830. 1:12:26peripheral polyneuropathy, and
  1831. 1:12:28sometimes mononeuritis multiplex. It is
  1832. 1:12:30also a cause of glomerulonephritis,
  1833. 1:12:32generally membranoproliferative. And
  1834. 1:12:34that is why I stressed that what seals
  1835. 1:12:37the diagnosis of cryoglobulinemia is
  1836. 1:12:40the laboratory. So here, just to
  1837. 1:12:42illustrate that image I told you about,
  1838. 1:12:44where cryoglobulin ends up sedimenting
  1839. 1:12:46when the sample is cooled, look. So
  1840. 1:12:49here at 4 ° C, for example, look, the
  1841. 1:12:51cryoglobulins settle at the bottom of
  1842. 1:12:54the tube. When the sample is reheated,
  1843. 1:12:57it dilutes again. So, testing for serum
  1844. 1:13:00cryoglobulins is fundamental for
  1845. 1:13:02diagnosis, but exam questions like to
  1846. 1:13:05bring up other findings. Can I have
  1847. 1:13:08elevated CRP, high ESR, normocytic
  1848. 1:13:11anemia? I can, but what you have to
  1849. 1:13:13remember is this right here. If it is a
  1850. 1:13:16vasculitis associated with immune
  1851. 1:13:18complex formation, which will join
  1852. 1:13:20cryoglobulin with complement components
  1853. 1:13:22, where will this complement come from
  1854. 1:13:24to form the immune complex? It will
  1855. 1:13:26come from the serum, from the blood.
  1856. 1:13:29Therefore, it is the first and only
  1857. 1:13:31vasculitis we will discuss here in
  1858. 1:13:33which we can find, and generally do
  1859. 1:13:35find, complement consumption, okay?
  1860. 1:13:37Mainly of the C4 fraction, but
  1861. 1:13:39eventually also C3. So this is a
  1862. 1:13:42fundamental piece of data. And another
  1863. 1:13:45thing that appears very frequently, and
  1864. 1:13:47which I haven't mentioned yet, is that
  1865. 1:13:50we can find a positive rheumatoid
  1866. 1:13:52factor in a good portion of patients
  1867. 1:13:54here. What happens here in
  1868. 1:13:56cryoglobulinemia? We have a sort of
  1869. 1:13:59overactivation of our B lymphocytes,
  1870. 1:14:02and so we have an overproduction of
  1871. 1:14:04immunoglobulins, of antibodies. But it
  1872. 1:14:07is a somewhat unbridled, nonspecific,
  1873. 1:14:10polyclonal production. So it will
  1874. 1:14:12produce ANA, which can be positive, and
  1875. 1:14:14it will produce rheumatoid factor,
  1876. 1:14:15which can be positive. So, if you see
  1877. 1:14:17vasculitis with a generic clinical
  1878. 1:14:19picture of small-vessel vasculitis, but
  1879. 1:14:21it has complement consumption, positive
  1880. 1:14:23rheumatoid factor, and positive serum
  1881. 1:14:25cryoglobulins, that's the way to nail
  1882. 1:14:27the diagnosis of cryo. Got it? Here,
  1883. 1:14:31just to clarify these points we
  1884. 1:14:33discussed, what really stands out here
  1885. 1:14:35is the lab work, especially the
  1886. 1:14:37complement consumption. And about
  1887. 1:14:39treatment, guys, you don't need to
  1888. 1:14:41memorize it, okay? Basically, you have
  1889. 1:14:43to treat hepatitis C, which is
  1890. 1:14:45fundamental here, and what will we use?
  1891. 1:14:47Corticosteroids, immunosuppressants.
  1892. 1:14:49That is all that is needed for the
  1893. 1:14:51management of cryo, okay? Now, a
  1894. 1:14:53question to show you exactly the
  1895. 1:14:55importance of what we just discussed, a
  1896. 1:14:56question from Sírio-Libanês. Let's go
  1897. 1:14:59. Here it mentions a 38-year-old woman
  1898. 1:15:02who develops arthralgia, purpura, and
  1899. 1:15:04weakness—very generic complaints,
  1900. 1:15:06right? And she was diagnosed—look at
  1901. 1:15:08the name it gives—with mixed
  1902. 1:15:10cryoglobulinemia syndrome. I told you
  1903. 1:15:12they might use different terms, and
  1904. 1:15:14it’s straightforward here. What is
  1905. 1:15:16the most common cause of this syndrome?
  1906. 1:15:18Don't be afraid. Mark hepatitis C
  1907. 1:15:21immediately. Cryo questions revolve
  1908. 1:15:24around this association the vast
  1909. 1:15:26majority of the time, okay? So, the
  1910. 1:15:29correct answer here is undoubtedly
  1911. 1:15:31hepatitis C, even knowing that several
  1912. 1:15:33other diseases cause the presence of
  1913. 1:15:34cryoglobulins, but it's asking for the
  1914. 1:15:36main one and there's no doubt here,
  1915. 1:15:38okay? So we've finished the
  1916. 1:15:41small-vessel ones here, excuse me. And
  1917. 1:15:44remembering that Henoch-Schönlein
  1918. 1:15:46purpura or IgA vasculitis can also
  1919. 1:15:48appear in adults, but its specific
  1920. 1:15:50study is back in pediatrics, okay? And
  1921. 1:15:52basically, you extend what you see in
  1922. 1:15:54pediatrics, in case it eventually
  1923. 1:15:56appears in an adult, which is quite
  1924. 1:15:58uncommon. The bulk of IgA vasculitis
  1925. 1:16:00questions is in childhood, which is why
  1926. 1:16:02it's studied in pediatrics, okay? Let's
  1927. 1:16:06move on then to our last two
  1928. 1:16:07vasculitides, which are those that can
  1929. 1:16:09affect vessels of all sizes, arteries,
  1930. 1:16:12veins, venules, capillaries, arterioles
  1931. 1:16:14, everything. They are two vasculitides
  1932. 1:16:17. Let's start with Behçet's syndrome
  1933. 1:16:19or Behçet's disease. Here we have a
  1934. 1:16:22clear predominance in young men and
  1935. 1:16:24women. Behçet's will hardly appear
  1936. 1:16:27after the age of 40 or 45. As I said,
  1937. 1:16:30it can affect any vessel. And here we
  1938. 1:16:32have to remember an epidemiological
  1939. 1:16:34association that sometimes appears on
  1940. 1:16:36exams. It is much more prevalent in
  1941. 1:16:39countries that were part of the ancient
  1942. 1:16:41Silk Road. So, taking that transition,
  1943. 1:16:44right, from Europe to Asia, Turkey,
  1944. 1:16:46reaching even the Far East, in the
  1945. 1:16:49Japan region. And there we also see a
  1946. 1:16:52very considerable prevalence of a
  1947. 1:16:54genetic risk factor that for Behçet's
  1948. 1:16:56syndrome is HLA-B 51. Remember that
  1949. 1:17:01when we talk about spondyloarthritis
  1950. 1:17:03it's HLA-B 27, here it's B51 and it's a
  1951. 1:17:06risk factor, it's not pathognomonic,
  1952. 1:17:09okay? So in Brazil, mainly, it is
  1953. 1:17:11present in a small portion of patients,
  1954. 1:17:13but sometimes on a test question, they
  1955. 1:17:14want to give a little hint, they
  1956. 1:17:16include this HLA. Okay? Regarding the
  1957. 1:17:19clinical picture, the base finding, the
  1958. 1:17:21pillar for you to think about Behçet's
  1959. 1:17:23syndrome is the ulcers. Painful and
  1960. 1:17:27recurrent oral and/or genital ulcers.
  1961. 1:17:30So here I even included an image of an
  1962. 1:17:32ulcer, look, on the lateral side of the
  1963. 1:17:34tongue. This can also appear on the
  1964. 1:17:37palate, the buccal mucosa, the genital
  1965. 1:17:39region, the labia majora. In men, it
  1966. 1:17:42can appear on the scrotum. So what
  1967. 1:17:44draws attention here is this painful
  1968. 1:17:46and recurrent character. But Behçet's
  1969. 1:17:48syndrome doesn't stop there. Other very
  1970. 1:17:51characteristic cutaneous findings are
  1971. 1:17:54erythema nodosum, which is what we see
  1972. 1:17:56here, look, nodular, painful,
  1973. 1:17:58infiltrated lesions that have this
  1974. 1:18:00hyperchromic aspect, predominantly on
  1975. 1:18:02the anterior aspect of the leg. So here
  1976. 1:18:05, look, this is very typical of
  1977. 1:18:07erythema nodosum. We also have
  1978. 1:18:08pseudofolliculitis-type lesions, the
  1979. 1:18:10ones that resemble acne. Regarding the
  1980. 1:18:13joints, arthralgia or arthritis,
  1981. 1:18:15nothing specific. BD really likes the
  1982. 1:18:18eyes and is a cause of uveitis. And
  1983. 1:18:22besides that, this inflammation can
  1984. 1:18:24occur in the anterior chamber of the
  1985. 1:18:26eye. And when it happens in the
  1986. 1:18:29anterior chamber of the eye, we can
  1987. 1:18:32have an accumulation of debris and
  1988. 1:18:35cellular remains. And what does that
  1989. 1:18:37form? The famous hypopyon, which can be
  1990. 1:18:40present in BD, or in spondyloarthritis,
  1991. 1:18:43okay? But here it is very
  1992. 1:18:45characteristic. So, if you see a
  1993. 1:18:47mention of hypopyon, remember Behçet's
  1994. 1:18:49disease. Moving on to other typical
  1995. 1:18:51involvements, remember the neurological
  1996. 1:18:53ones. And here it’s the central
  1997. 1:18:55nervous system, unlike what we’ve
  1998. 1:18:57been discussing until now, generally
  1999. 1:18:59about forms of meningitis or aseptic
  2000. 1:19:01meningoencephalitis. Here there is no
  2001. 1:19:03herpes, no bacteria involved. The
  2002. 1:19:05clinical picture is quite similar, but
  2003. 1:19:07there is no infection involved. BD is a
  2004. 1:19:10classic cause of thrombosis, but it's
  2005. 1:19:12not a blood clot-based thrombosis; it's
  2006. 1:19:15not a thrombophilia, nothing like that.
  2007. 1:19:19BD causes so much inflammation in the
  2008. 1:19:21vessel wall that highly inflammatory
  2009. 1:19:24thrombi can form, both arterial and
  2010. 1:19:26venous, which can appear anywhere, okay
  2011. 1:19:29? And still from a vascular standpoint,
  2012. 1:19:33BD has a finding that is practically
  2013. 1:19:35pathognomonic. We can't state it with
  2014. 1:19:38100%certainty, but for your exam and
  2015. 1:19:41for your life, look: Pulmonary artery
  2016. 1:19:43aneurysm; by far the first, second, and
  2017. 1:19:46third diagnostic hypotheses should be
  2018. 1:19:48Behçet's disease, okay? To finish, BD
  2019. 1:19:52requires a differential diagnosis with
  2020. 1:19:54inflammatory bowel disease when it
  2021. 1:19:56affects the intestines, because it
  2022. 1:19:58creates a picture very similar to
  2023. 1:19:59Crohn's or ulcerative colitis; they
  2024. 1:20:01have other things in common, right?
  2025. 1:20:04Erythema nodosum, uveitis. So it is a
  2026. 1:20:06major differential diagnosis. And to
  2027. 1:20:09summarize, to consider BD, think of a
  2028. 1:20:11young adult, man or woman, who, in
  2029. 1:20:13addition to recurrent and painful
  2030. 1:20:15ulcers, presents with uveitis, erythema
  2031. 1:20:18nodosum, thrombosis, or some central
  2032. 1:20:20nervous system complaint, okay? So, in
  2033. 1:20:23general, that is the profile of BD. As
  2034. 1:20:25for lab tests, nothing specific. The
  2035. 1:20:28only thing I want to highlight, which
  2036. 1:20:30may appear on exams, is this test, the
  2037. 1:20:32pathergy test, okay? In the pathergy
  2038. 1:20:34test, what do we do? We take a needle,
  2039. 1:20:37we insert it into the patient's skin at
  2040. 1:20:40a specific angle and depth, and we wait
  2041. 1:20:4248 hours to reevaluate whether this
  2042. 1:20:45needle insertion caused any local
  2043. 1:20:47reaction. Why? The pathophysiology of
  2044. 1:20:51BD involves neutrophil activation. So,
  2045. 1:20:54this neutrophilic vascular reaction
  2046. 1:20:56where I inserted the needle is
  2047. 1:20:58favorable for a BD diagnosis, but it is
  2048. 1:21:01not specific. It can also appear in
  2049. 1:21:03other conditions, okay? In general,
  2050. 1:21:05when pathergy appears on your exam,
  2051. 1:21:07it's time for you to think of BD, okay?
  2052. 1:21:10To wrap up, no need to memorize this.
  2053. 1:21:12Treatment depends on the manifestation.
  2054. 1:21:15Corticosteroids are super important as
  2055. 1:21:17eye drops for uveitis, for treating
  2056. 1:21:20systemic manifestations, and even
  2057. 1:21:22topically to help treat ulcers for
  2058. 1:21:25manifestations such as joint
  2059. 1:21:27involvement, neurological involvement,
  2060. 1:21:30or vascular involvement. However, the
  2061. 1:21:33dosage and administration of the
  2062. 1:21:35corticosteroid change accordingly.
  2063. 1:21:37Immunosuppressants here for severe,
  2064. 1:21:39refractory cases, for example,
  2065. 1:21:41thrombosis, pulmonary artery aneurysm,
  2066. 1:21:43neurological involvement, okay? So it's
  2067. 1:21:45the same foundation we've discussed so
  2068. 1:21:47far. What will change radically here is
  2069. 1:21:50the next vasculitis, which won't have
  2070. 1:21:52any of this in the treatment, okay? But
  2071. 1:21:54to finish BD, let's solve a question.
  2072. 1:21:57This one from CESPE, look. A 28-
  2073. 1:22:00year-old patient with oral ulcers for 2
  2074. 1:22:03years and, more recently, visual
  2075. 1:22:06complaints, blurring, lower limb
  2076. 1:22:08lesions, and episodes of hemoptysis.
  2077. 1:22:13This set off all the alarms for BD.
  2078. 1:22:16During the investigation, the visual
  2079. 1:22:18blurring is due to panuveitis. The skin
  2080. 1:22:20lesions on the lower limbs are erythema
  2081. 1:22:23nodosum, and the hemoptysis is caused
  2082. 1:22:25by what? By pulmonary artery aneurysms.
  2083. 1:22:29There's no doubt about it, folks. This
  2084. 1:22:30basically described the classic
  2085. 1:22:32clinical picture of BD that we've
  2086. 1:22:34discussed so far, especially when it
  2087. 1:22:36presents this involvement of pulmonary
  2088. 1:22:39arteries with the formation of
  2089. 1:22:41aneurysms. As I said, it is practically
  2090. 1:22:43pathognomonic. So, a very interesting
  2091. 1:22:45question, presenting a very
  2092. 1:22:46characteristic picture of Behçet's
  2093. 1:22:48syndrome. So, look, if you finish this
  2094. 1:22:51class able to recognize the patterns of
  2095. 1:22:53each of these vasculitides, look, there
  2096. 1:22:55were several present in the statement.
  2097. 1:22:58If you look at it and recognize each
  2098. 1:23:00one, you solve these questions that
  2099. 1:23:02sometimes, often actually, are
  2100. 1:23:03considered difficult, okay? And to
  2101. 1:23:06really finish, thromboangiitis
  2102. 1:23:08obliterans, or Buerger's disease, is
  2103. 1:23:10appearing more and more on exams, okay?
  2104. 1:23:13It can show up in the clinical block,
  2105. 1:23:15it can show up in the surgery block,
  2106. 1:23:16because it's a differential diagnosis
  2107. 1:23:18for peripheral artery disease, okay?
  2108. 1:23:20Let's go. Here we basically have adult
  2109. 1:23:24men who present with a vasculopathy,
  2110. 1:23:26which by biopsy, by definition, we call
  2111. 1:23:28vasculitis because it is inflammatory.
  2112. 1:23:31And what happens here? The name of the
  2113. 1:23:33disease under study. I have an
  2114. 1:23:35inflammatory process in the blood
  2115. 1:23:37vessel, angiitis, which will lead to
  2116. 1:23:39the formation of thrombi, and these
  2117. 1:23:41thrombi will obliterate the lumen of
  2118. 1:23:43these vessels, causing what? Ischemia.
  2119. 1:23:47It's basically breaking down the name
  2120. 1:23:49of the disease and you discover what it
  2121. 1:23:51does. So, adult men, and for you to
  2122. 1:23:54think about thromboangiitis obliterans,
  2123. 1:23:56there is a condition that, according to
  2124. 1:23:58most authors, is considered sine qua
  2125. 1:24:00non. To have thromboangiitis obliterans
  2126. 1:24:04, you need the patient to be a smoker.
  2127. 1:24:07So, the question will bring this to you
  2128. 1:24:09; in the alternatives, it will test you
  2129. 1:24:11, there must be exposure to nicotine.
  2130. 1:24:14The patient must be a smoker, okay?
  2131. 1:24:17This is a very strong relationship.
  2132. 1:24:18There has been an ENADE question that
  2133. 1:24:20asked for the disease that has the
  2134. 1:24:21strongest relationship with cigarettes.
  2135. 1:24:24It listed several for which smoking is
  2136. 1:24:26a risk factor, stroke, heart attack,
  2137. 1:24:29but here there's no way around it, it's
  2138. 1:24:31a practically total association
  2139. 1:24:33strength. Many authors state that the
  2140. 1:24:36pathophysiological process, this
  2141. 1:24:37inflammatory process in the vessel,
  2142. 1:24:39only happens in these patients who, in
  2143. 1:24:41general, have a genetic predisposition,
  2144. 1:24:43susceptibility combined with cigarette
  2145. 1:24:45use. So this is the main thing about
  2146. 1:24:47this vasculitis, okay? Regarding the
  2147. 1:24:49clinical presentation, this ischemia
  2148. 1:24:51starts in a mild initial form, and then
  2149. 1:24:53the patient will present with Raynaud's
  2150. 1:24:55phenomenon, migratory thrombophlebitis.
  2151. 1:24:58This also appears a lot in the
  2152. 1:24:59questions. And then, once this ischemia
  2153. 1:25:02is established and definitive, the
  2154. 1:25:05phenomena of claudication begin,
  2155. 1:25:07vascular claudication, mainly in the
  2156. 1:25:10lower limbs, but sometimes in the upper
  2157. 1:25:13ones. And with the disease already
  2158. 1:25:15well-established, what is left?
  2159. 1:25:17Necrosis, gangrene. So this here, what
  2160. 1:25:21happens at the tip of this patient's
  2161. 1:25:23finger, is the classic case of
  2162. 1:25:25untreated thromboangiitis obliterans,
  2163. 1:25:27okay? There's nothing in the lab
  2164. 1:25:29results here to draw attention to; it's
  2165. 1:25:30all very nonspecific. The test of
  2166. 1:25:32choice, if I want to make the diagnosis
  2167. 1:25:34, is arteriography. As it has already
  2168. 1:25:35appeared in one question or another, I
  2169. 1:25:37brought the image. In this
  2170. 1:25:39arteriography, we do have normal
  2171. 1:25:41vascular segments alternating with
  2172. 1:25:43points of stenosis. We are talking
  2173. 1:25:46about a vasculitis, but what draws
  2174. 1:25:48attention here is the formation of a
  2175. 1:25:50network of collaterals, the so-called
  2176. 1:25:51corkscrew-like or spiderweb-like
  2177. 1:25:53appearance network. So, it obstructs a
  2178. 1:25:56vessel and several other smaller ones
  2179. 1:25:58end up being formed, okay? So that is
  2180. 1:26:01what stands out in thromboangiitis
  2181. 1:26:03obliterans. There is stenosis, there is
  2182. 1:26:05a stop in blood flow, but a collateral
  2183. 1:26:07network also forms with this corkscrew
  2184. 1:26:09appearance. And I told you it was a
  2185. 1:26:12non-inflammatory vasculitis. Here, it's
  2186. 1:26:15no use using corticosteroids or
  2187. 1:26:16immunosuppressants; none of that is
  2188. 1:26:18indicated. If the patient doesn't stop
  2189. 1:26:22smoking, you simply cannot treat this
  2190. 1:26:24vasculitis. So the first and most
  2191. 1:26:26important measure is smoking cessation.
  2192. 1:26:30And then, of course, vascular care,
  2193. 1:26:32local care, maybe surgical measures can
  2194. 1:26:35be implemented, but nothing works if
  2195. 1:26:37there is no smoking cessation, okay? To
  2196. 1:26:40finish, a Unicamp question, quite nice,
  2197. 1:26:42discursive, with a very typical
  2198. 1:26:44clinical picture, look. An adult man
  2199. 1:26:47who presents a very painful lesion on
  2200. 1:26:49the tip, on the extremity of the right
  2201. 1:26:51big toe, and a lesion that won't heal,
  2202. 1:26:54which appeared two months ago. The pain
  2203. 1:26:57is so strong, and note that it has
  2204. 1:26:59neuropathic characteristics; a burning
  2205. 1:27:01pain, a more nocturnal pain, the
  2206. 1:27:03patient cannot sleep. And so, how does
  2207. 1:27:06he end up feeling better? When he goes
  2208. 1:27:09there and rubs his foot with his hands,
  2209. 1:27:12he warms up the area. Regarding his
  2210. 1:27:16history, he is a smoker, which is very
  2211. 1:27:18important. He has a history of
  2212. 1:27:20superficial thrombophlebitis in the
  2213. 1:27:22upper limb and in the left lower limb 7
  2214. 1:27:24months ago. And on physical examination
  2215. 1:27:27, what stands out? On his foot, he has
  2216. 1:27:29no hair. Here we already flag, right,
  2217. 1:27:33the possibility of some local arterial
  2218. 1:27:35involvement, the skin is thinner,
  2219. 1:27:37shinier. So, in fact, it seems there is
  2220. 1:27:40a deficit here in arterial circulation.
  2221. 1:27:44And at the site where he reports this
  2222. 1:27:46extreme pain, this very strong pain, he
  2223. 1:27:48has erythema, an inflammatory erythema.
  2224. 1:27:52Regarding pulses, what do we notice?
  2225. 1:27:55That at the site where he has this
  2226. 1:27:57ischemic, painful, inflammatory lesion,
  2227. 1:28:00there is no pulse. There is no pulse.
  2228. 1:28:02Why? Because he has thromboangiitis
  2229. 1:28:06obliterans, he is a smoker, his
  2230. 1:28:08circulation is compromised, closed off
  2231. 1:28:10to that hallux, and what did he develop
  2232. 1:28:12? He developed an ischemic lesion that
  2233. 1:28:15hurts like hell, okay? He has a history
  2234. 1:28:18of superficial thrombophlebitis, so
  2235. 1:28:20it’s the spitting image of
  2236. 1:28:21Buerger’s disease; so much so that
  2237. 1:28:23this was the answer for that Unicamp
  2238. 1:28:25discursive question, okay? And that is
  2239. 1:28:27how we end this class. A lot of
  2240. 1:28:29information, right, guys? Phew, it's a
  2241. 1:28:30lot of vasculitis, but there's no way
  2242. 1:28:32around it. All of them appear on exams.
  2243. 1:28:34Currently, the ones that appear more
  2244. 1:28:36frequently are large-vessel vasculitis.
  2245. 1:28:39Wegener's also appears with relative
  2246. 1:28:41frequency, and thromboangiitis
  2247. 1:28:42obliterans, okay? So, I would keep a
  2248. 1:28:45closer eye on these processes, but you
  2249. 1:28:46need basic knowledge of each one,
  2250. 1:28:48especially because in exam questions,
  2251. 1:28:50the differential diagnoses presented
  2252. 1:28:52are often other vasculitis. So you have
  2253. 1:28:55to remember the "face" or the clinical
  2254. 1:28:56picture of each one to solve the puzzle
  2255. 1:28:58, okay? If you have any questions,
  2256. 1:29:00leave them here in the student forum or
  2257. 1:29:02on my Instagram @profitaMoreira, and
  2258. 1:29:04I'll see you next time. Kisses, bye-bye
  2259. 1:29:06, and see you later. All set, everyone.
  2260. 1:29:18I told you I'd finish the class and
  2261. 1:29:19come back, right? I know it's a tiring
  2262. 1:29:22class, I know there are 500 topics, but
  2263. 1:29:23there's no way to break them up. All
  2264. 1:29:25these vasculitis are related to each
  2265. 1:29:27other, but at the same time, they have
  2266. 1:29:30their own peculiarities. So, we need to
  2267. 1:29:32concentrate them in one class so you
  2268. 1:29:34can memorize the "face" of each one,
  2269. 1:29:36okay? Let's check the chat to see if
  2270. 1:29:38there are any questions. Jane,
  2271. 1:29:39regarding cryoglobulinemia with
  2272. 1:29:41hepatitis C, I just treat the hepatitis
  2273. 1:29:43C. The first thing you're going to
  2274. 1:29:45treat, Jane, is the hepatitis C. So you
  2275. 1:29:47go after it, do the serology, but you
  2276. 1:29:49really need the molecular test to show
  2277. 1:29:52there's viral replication of the C
  2278. 1:29:54virus, because what feeds the
  2279. 1:29:55cryoglobulinemia is the virus
  2280. 1:29:57replication. That is what allows for
  2281. 1:29:59the formation of those immune complexes
  2282. 1:30:01. So, sometimes, just by treating the
  2283. 1:30:03hepatitis C, we can already manage the
  2284. 1:30:05cryo well. More symptomatic treatments,
  2285. 1:30:09like corticosteroids, and eventually
  2286. 1:30:10immunomodulatory and immunosuppressive
  2287. 1:30:12drugs, may be necessary when you
  2288. 1:30:14already have a more established
  2289. 1:30:16systemic condition, such as cutaneous
  2290. 1:30:18vasculitis, glomerulonephritis, or
  2291. 1:30:19peripheral neuropathic involvement. But
  2292. 1:30:22undoubtedly, the first measure for cryo
  2293. 1:30:24associated with hepatitis C is to treat
  2294. 1:30:26the hepatitis C, okay? The rest ends up
  2295. 1:30:28being symptomatic treatment that we
  2296. 1:30:30perform, okay? Let's go. Let me see
  2297. 1:30:33here. I think there was another one.
  2298. 1:30:34Jane also asked about polymyalgia.
  2299. 1:30:36Polymyalgia is treated with
  2300. 1:30:37corticosteroids, okay? Generally 10, 15
  2301. 1:30:39, or at most 20 mg. The patient
  2302. 1:30:41responds well and responds quickly. And
  2303. 1:30:43then, to spare corticosteroids, use a
  2304. 1:30:45synthetic immunosuppressant, okay?
  2305. 1:30:47Methotrexate works very well, generally
  2306. 1:30:48it's what we use most, but if
  2307. 1:30:50methotrexate doesn't work, leflunomide.
  2308. 1:30:52I personally have never had a case of
  2309. 1:30:54polymyalgia rheumatica refractory to
  2310. 1:30:56synthetic immunosuppressants that
  2311. 1:30:58required an immunobiologic. In those
  2312. 1:31:00cases, I think it's better to even
  2313. 1:31:01review the diagnosis, because the
  2314. 1:31:02improvement with corticosteroids is
  2315. 1:31:04remarkable. Then you use the synthetic
  2316. 1:31:07immunosuppressant just to spare the
  2317. 1:31:08corticosteroid and allow you to wean it
  2318. 1:31:10off with the disease well-controlled at
  2319. 1:31:12its source. All right, everyone? Any
  2320. 1:31:15other questions? I don't think so,
  2321. 1:31:16right? I think that was it. So that's
  2322. 1:31:18it. Thank you very much, everyone. Juan
  2323. 1:31:20, thank you very much. For the great
  2324. 1:31:21class. Thank you, Juan. Always here
  2325. 1:31:23with us. Ana, thank you, my dear.
  2326. 1:31:26Augusto, I'm the one who should thank
  2327. 1:31:27you, guys. I'm the one who thanks you
  2328. 1:31:29for being here for another class this
  2329. 1:31:30Wednesday. Remembering that next week,
  2330. 1:31:33on Tuesday, at 7:30, I'll be here
  2331. 1:31:35solving R + Medical Residency, Reato,
  2332. 1:31:38Pain Medicine, and Palliative Care
  2333. 1:31:40questions. And on Wednesday we have a
  2334. 1:31:43new meeting with a class. I also think
  2335. 1:31:45it's a class from our intensive course,
  2336. 1:31:46anyway, but we have meetings scheduled
  2337. 1:31:48for next week too, okay? Any questions,
  2338. 1:31:51leave them on my Instagram, @
  2339. 1:31:52profaiísira. And now let's get some
  2340. 1:31:54rest. I'll see you all at our next
  2341. 1:31:57meetings, okay? A big kiss to each one
  2342. 1:31:59of you. Bye-bye and see you later. When
  2343. 1:32:30I started using it, I felt very secure,
  2344. 1:32:32and today the results I have aren't by
  2345. 1:32:34chance. So, without a doubt, of course
  2346. 1:32:36our effort is worth it, but the
  2347. 1:32:38professors took me by the hand with the
  2348. 1:32:40materials and helped me get there.
  2349. 1:32:42Studying for hours straight like that
  2350. 1:32:43didn't work for me. So, very long
  2351. 1:32:45classes are hard to get through. So,
  2352. 1:32:47having material, whether in class, text
  2353. 1:32:49, or flashcards, that is a bit more
  2354. 1:32:52fragmented helps us study a bit more at
  2355. 1:32:54our own pace, right? This schedule also
  2356. 1:32:58helped me stay on track, and, like you
  2357. 1:32:59said, the multiple platforms help. When
  2358. 1:33:03I had some time, I would either read a
  2359. 1:33:05summary, do some questions, a question
  2360. 1:33:06list, a short class, a summary lecture,
  2361. 1:33:08or even listen to a podcast, which
  2362. 1:33:10helps us try to make the most of the
  2363. 1:33:12time we have, especially since things
  2364. 1:33:14have become more hectic these days.
  2365. 1:33:16Right?
  2366. 1:33:17And so I tested it and said: "This is
  2367. 1:33:19the course I'm going to take." It's a
  2368. 1:33:21fair course, the classes are very good,
  2369. 1:33:23straight to the point, and it's
  2370. 1:33:25teaching exactly what I need to know.
  2371. 1:33:28And honestly, most of my questions,
  2372. 1:33:30even though I sent a million of them,
  2373. 1:33:32were answered by the classes and the
  2374. 1:33:34books. So I totally agree and I would
  2375. 1:33:37do it again. I think Estratégia
  2376. 1:33:40provides great guidance on what is
  2377. 1:33:43important to study, so you don't waste
  2378. 1:33:46time on things you can go through
  2379. 1:33:48faster, allowing you to be objective in
  2380. 1:33:51what you set out to do. What I liked,
  2381. 1:33:55what I liked most was that; it was a
  2382. 1:33:58methodology that helped me a lot,
  2383. 1:34:00especially the spaced repetition and
  2384. 1:34:02the question-solving methodology that
  2385. 1:34:05had guidance within the question itself
  2386. 1:34:08. I felt that everything was very well
  2387. 1:34:11structured and very well organized
  2388. 1:34:12within that study plan. For me, that
  2389. 1:34:14helped a lot.

About this transcript

This page contains the full transcript of Vasculites: Aula de Curso Intensivo Residência Médica com Profa. Taysa Moreira by Estratégia MED, generated from the public captions YouTube serves with the video. The transcript has 14,456 words across 2,389 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.

What you can do with it

Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.

Free YouTube transcript tool

YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.